#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Regional Homogeneity Changes in Nicotine Addicts by Resting-State fMRI
#Text=Objective
#Text=To reveal the brain functional changes of nicotine addicts compared with those of non-smokers and explore the objective biomarker for nicotine dependence evaluation.
1-1	0-8	Regional	_	
1-2	9-20	Homogeneity	_	
1-3	21-28	Changes	_	
1-4	29-31	in	_	
1-5	32-40	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[1]	
1-6	41-48	Addicts	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[1]	
1-7	49-51	by	_	
1-8	52-65	Resting-State	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-9	66-70	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[2]	
1-10	71-80	Objective	_	
1-11	81-83	To	_	
1-12	84-90	reveal	_	
1-13	91-94	the	_	
1-14	95-100	brain	_	
1-15	101-111	functional	_	
1-16	112-119	changes	_	
1-17	120-122	of	_	
1-18	123-131	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[3]	
1-19	132-139	addicts	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[3]	
1-20	140-148	compared	_	
1-21	149-153	with	_	
1-22	154-159	those	_	
1-23	160-162	of	_	
1-24	163-174	non-smokers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
1-25	175-178	and	_	
1-26	179-186	explore	_	
1-27	187-190	the	_	
1-28	191-200	objective	_	
1-29	201-210	biomarker	_	
1-30	211-214	for	_	
1-31	215-223	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[4]	
1-32	224-234	dependence	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[4]	
1-33	235-245	evaluation	_	
1-34	245-246	.	_	

#Text=Methods
#Text=A total of 14 smokers and 11 non-smoking controls were recruited for this study.
2-1	247-254	Methods	_	
2-2	255-256	A	_	
2-3	257-262	total	_	
2-4	263-265	of	_	
2-5	266-268	14	_	
2-6	269-276	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
2-7	277-280	and	_	
2-8	281-283	11	_	
2-9	284-295	non-smoking	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
2-10	296-304	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
2-11	305-309	were	_	
2-12	310-319	recruited	_	
2-13	320-323	for	_	
2-14	324-328	this	_	
2-15	329-334	study	_	
2-16	334-335	.	_	

#Text=Resting-state functional magnetic resonance imaging and regional homogeneity (ReHo) were applied in the neural activity analysis.
3-1	336-349	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[6]	
3-2	350-360	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[6]	
3-3	361-369	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[6]	
3-4	370-379	resonance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[6]	
3-5	380-387	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[6]	
3-6	388-391	and	_	
3-7	392-400	regional	_	
3-8	401-412	homogeneity	_	
3-9	413-414	(	_	
3-10	414-418	ReHo	_	
3-11	418-419	)	_	
3-12	420-424	were	_	
3-13	425-432	applied	_	
3-14	433-435	in	_	
3-15	436-439	the	_	
3-16	440-446	neural	_	
3-17	447-455	activity	_	
3-18	456-464	analysis	_	
3-19	464-465	.	_	

#Text=Two-sample t-test was performed to examine the voxel-wise difference between the smokers and the controls.
4-1	466-476	Two-sample	_	
4-2	477-483	t-test	_	
4-3	484-487	was	_	
4-4	488-497	performed	_	
4-5	498-500	to	_	
4-6	501-508	examine	_	
4-7	509-512	the	_	
4-8	513-523	voxel-wise	_	
4-9	524-534	difference	_	
4-10	535-542	between	_	
4-11	543-546	the	_	
4-12	547-554	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
4-13	555-558	and	_	
4-14	559-562	the	_	
4-15	563-571	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
4-16	571-572	.	_	

#Text=Correlation analysis between the ReHo values and the Fagerstrom Test for Nicotine Dependence (FTND) scores were performed to explore the biomarkers for the clinical characteristics of smokers.
5-1	573-584	Correlation	_	
5-2	585-593	analysis	_	
5-3	594-601	between	_	
5-4	602-605	the	_	
5-5	606-610	ReHo	_	
5-6	611-617	values	_	
5-7	618-621	and	_	
5-8	622-625	the	_	
5-9	626-636	Fagerstrom	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[7]	
5-10	637-641	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[7]	
5-11	642-645	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[7]	
5-12	646-654	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[7]	
5-13	655-665	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[7]	
5-14	666-667	(	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[7]	
5-15	667-671	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[7]	
5-16	671-672	)	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[7]	
5-17	673-679	scores	_	
5-18	680-684	were	_	
5-19	685-694	performed	_	
5-20	695-697	to	_	
5-21	698-705	explore	_	
5-22	706-709	the	_	
5-23	710-720	biomarkers	_	
5-24	721-724	for	_	
5-25	725-728	the	_	
5-26	729-737	clinical	_	
5-27	738-753	characteristics	_	
5-28	754-756	of	_	
5-29	757-764	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
5-30	764-765	.	_	

#Text=Results
#Text=The ReHo values from the right superior frontal gyrus of the Brodmann’s area (BA) 9 to the right middle frontal gyrus and the ReHo value from the left and right precuneus (BA 23) to the left and right middle cingulum gyrus were lower in the smokers than in the non-smokers.
6-1	766-773	Results	_	
6-2	774-777	The	_	
6-3	778-782	ReHo	_	
6-4	783-789	values	_	
6-5	790-794	from	_	
6-6	795-798	the	_	
6-7	799-804	right	_	
6-8	805-813	superior	_	
6-9	814-821	frontal	_	
6-10	822-827	gyrus	_	
6-11	828-830	of	_	
6-12	831-834	the	_	
6-13	835-843	Brodmann	_	
6-14	843-844	’	_	
6-15	844-845	s	_	
6-16	846-850	area	_	
6-17	851-852	(	_	
6-18	852-854	BA	_	
6-19	854-855	)	_	
6-20	856-857	9	_	
6-21	858-860	to	_	
6-22	861-864	the	_	
6-23	865-870	right	_	
6-24	871-877	middle	_	
6-25	878-885	frontal	_	
6-26	886-891	gyrus	_	
6-27	892-895	and	_	
6-28	896-899	the	_	
6-29	900-904	ReHo	_	
6-30	905-910	value	_	
6-31	911-915	from	_	
6-32	916-919	the	_	
6-33	920-924	left	_	
6-34	925-928	and	_	
6-35	929-934	right	_	
6-36	935-944	precuneus	_	
6-37	945-946	(	_	
6-38	946-948	BA	_	
6-39	949-951	23	_	
6-40	951-952	)	_	
6-41	953-955	to	_	
6-42	956-959	the	_	
6-43	960-964	left	_	
6-44	965-968	and	_	
6-45	969-974	right	_	
6-46	975-981	middle	_	
6-47	982-990	cingulum	_	
6-48	991-996	gyrus	_	
6-49	997-1001	were	_	
6-50	1002-1007	lower	_	
6-51	1008-1010	in	_	
6-52	1011-1014	the	_	
6-53	1015-1022	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
6-54	1023-1027	than	_	
6-55	1028-1030	in	_	
6-56	1031-1034	the	_	
6-57	1035-1046	non-smokers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
6-58	1046-1047	.	_	

#Text=The ReHo value in the precuneus (BA 23) was significantly and positively correlated with the FTND score of smokers.
7-1	1048-1051	The	_	
7-2	1052-1056	ReHo	_	
7-3	1057-1062	value	_	
7-4	1063-1065	in	_	
7-5	1066-1069	the	_	
7-6	1070-1079	precuneus	_	
7-7	1080-1081	(	_	
7-8	1081-1083	BA	_	
7-9	1084-1086	23	_	
7-10	1086-1087	)	_	
7-11	1088-1091	was	_	
7-12	1092-1105	significantly	_	
7-13	1106-1109	and	_	
7-14	1110-1120	positively	_	
7-15	1121-1131	correlated	_	
7-16	1132-1136	with	_	
7-17	1137-1140	the	_	
7-18	1141-1145	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence	
7-19	1146-1151	score	_	
7-20	1152-1154	of	_	
7-21	1155-1162	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
7-22	1162-1163	.	_	

#Text=Conclusion
#Text=The ReHo values in the right superior frontal gyrus and left precuneus can be used to separate the smokers from the non-smokers.
8-1	1164-1174	Conclusion	_	
8-2	1175-1178	The	_	
8-3	1179-1183	ReHo	_	
8-4	1184-1190	values	_	
8-5	1191-1193	in	_	
8-6	1194-1197	the	_	
8-7	1198-1203	right	_	
8-8	1204-1212	superior	_	
8-9	1213-1220	frontal	_	
8-10	1221-1226	gyrus	_	
8-11	1227-1230	and	_	
8-12	1231-1235	left	_	
8-13	1236-1245	precuneus	_	
8-14	1246-1249	can	_	
8-15	1250-1252	be	_	
8-16	1253-1257	used	_	
8-17	1258-1260	to	_	
8-18	1261-1269	separate	_	
8-19	1270-1273	the	_	
8-20	1274-1281	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
8-21	1282-1286	from	_	
8-22	1287-1290	the	_	
8-23	1291-1302	non-smokers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
8-24	1302-1303	.	_	

#Text=In particular, the left precuneus is a potential neuroimaging biomarker for nicotine addicts.
9-1	1304-1306	In	_	
9-2	1307-1317	particular	_	
9-3	1317-1318	,	_	
9-4	1319-1322	the	_	
9-5	1323-1327	left	_	
9-6	1328-1337	precuneus	_	
9-7	1338-1340	is	_	
9-8	1341-1342	a	_	
9-9	1343-1352	potential	_	
9-10	1353-1365	neuroimaging	_	
9-11	1366-1375	biomarker	_	
9-12	1376-1379	for	_	
9-13	1380-1388	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[8]	
9-14	1389-1396	addicts	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[8]	
9-15	1396-1397	.	_	

#Text=Introduction
#Text=Smoking causes many kinds of diseases, such as ischemic heart disease, cerebral vascular disease, lower respiratory tract infection, chronic obstructive pulmonary disease, tuberculosis, and lung cancer.
10-1	1398-1410	Introduction	_	
10-2	1411-1418	Smoking	_	
10-3	1419-1425	causes	_	
10-4	1426-1430	many	_	
10-5	1431-1436	kinds	_	
10-6	1437-1439	of	_	
10-7	1440-1448	diseases	_	
10-8	1448-1449	,	_	
10-9	1450-1454	such	_	
10-10	1455-1457	as	_	
10-11	1458-1466	ischemic	_	
10-12	1467-1472	heart	_	
10-13	1473-1480	disease	_	
10-14	1480-1481	,	_	
10-15	1482-1490	cerebral	_	
10-16	1491-1499	vascular	_	
10-17	1500-1507	disease	_	
10-18	1507-1508	,	_	
10-19	1509-1514	lower	_	
10-20	1515-1526	respiratory	_	
10-21	1527-1532	tract	_	
10-22	1533-1542	infection	_	
10-23	1542-1543	,	_	
10-24	1544-1551	chronic	_	
10-25	1552-1563	obstructive	_	
10-26	1564-1573	pulmonary	_	
10-27	1574-1581	disease	_	
10-28	1581-1582	,	_	
10-29	1583-1595	tuberculosis	_	
10-30	1595-1596	,	_	
10-31	1597-1600	and	_	
10-32	1601-1605	lung	_	
10-33	1606-1612	cancer	_	
10-34	1612-1613	.	_	

#Text=Nicotine addicts often experience psychological and emotional changes.
11-1	1614-1622	Nicotine	_	
11-2	1623-1630	addicts	_	
11-3	1631-1636	often	_	
11-4	1637-1647	experience	_	
11-5	1648-1661	psychological	_	
11-6	1662-1665	and	_	
11-7	1666-1675	emotional	_	
11-8	1676-1683	changes	_	
11-9	1683-1684	.	_	

#Text=Do et al. discovered that functional coupling between striatal and cortical regions is associated with increased craving in adolescent smokers.
12-1	1685-1687	Do	_	
12-2	1688-1690	et	_	
12-3	1691-1693	al	_	
12-4	1693-1694	.	_	
12-5	1695-1705	discovered	_	
12-6	1706-1710	that	_	
12-7	1711-1721	functional	_	
12-8	1722-1730	coupling	_	
12-9	1731-1738	between	_	
12-10	1739-1747	striatal	_	
12-11	1748-1751	and	_	
12-12	1752-1760	cortical	_	
12-13	1761-1768	regions	_	
12-14	1769-1771	is	_	
12-15	1772-1782	associated	_	
12-16	1783-1787	with	_	
12-17	1788-1797	increased	_	
12-18	1798-1805	craving	_	
12-19	1806-1808	in	_	
12-20	1809-1819	adolescent	_	
12-21	1820-1827	smokers	_	
12-22	1827-1828	.	_	

#Text=Sutherland et al. observed that smoking is associated with convergent structural decreases in the left insula, right cerebellum, parahippocampus, multiple prefrontal cortex regions, and the thalamus.
13-1	1829-1839	Sutherland	_	
13-2	1840-1842	et	_	
13-3	1843-1845	al	_	
13-4	1845-1846	.	_	
13-5	1847-1855	observed	_	
13-6	1856-1860	that	_	
13-7	1861-1868	smoking	_	
13-8	1869-1871	is	_	
13-9	1872-1882	associated	_	
13-10	1883-1887	with	_	
13-11	1888-1898	convergent	_	
13-12	1899-1909	structural	_	
13-13	1910-1919	decreases	_	
13-14	1920-1922	in	_	
13-15	1923-1926	the	_	
13-16	1927-1931	left	_	
13-17	1932-1938	insula	_	
13-18	1938-1939	,	_	
13-19	1940-1945	right	_	
13-20	1946-1956	cerebellum	_	
13-21	1956-1957	,	_	
13-22	1958-1973	parahippocampus	_	
13-23	1973-1974	,	_	
13-24	1975-1983	multiple	_	
13-25	1984-1994	prefrontal	_	
13-26	1995-2001	cortex	_	
13-27	2002-2009	regions	_	
13-28	2009-2010	,	_	
13-29	2011-2014	and	_	
13-30	2015-2018	the	_	
13-31	2019-2027	thalamus	_	
13-32	2027-2028	.	_	

#Text=Mcclernon et al. provided evidence that abstinence-induced deficits in working memory and changes in the underlying brain function are mostly due to abstinence from nicotine rather than non-nicotine factors.
14-1	2029-2038	Mcclernon	_	
14-2	2039-2041	et	_	
14-3	2042-2044	al	_	
14-4	2044-2045	.	_	
14-5	2046-2054	provided	_	
14-6	2055-2063	evidence	_	
14-7	2064-2068	that	_	
14-8	2069-2087	abstinence-induced	_	
14-9	2088-2096	deficits	_	
14-10	2097-2099	in	_	
14-11	2100-2107	working	_	
14-12	2108-2114	memory	_	
14-13	2115-2118	and	_	
14-14	2119-2126	changes	_	
14-15	2127-2129	in	_	
14-16	2130-2133	the	_	
14-17	2134-2144	underlying	_	
14-18	2145-2150	brain	_	
14-19	2151-2159	function	_	
14-20	2160-2163	are	_	
14-21	2164-2170	mostly	_	
14-22	2171-2174	due	_	
14-23	2175-2177	to	_	
14-24	2178-2188	abstinence	_	
14-25	2189-2193	from	_	
14-26	2194-2202	nicotine	_	
14-27	2203-2209	rather	_	
14-28	2210-2214	than	_	
14-29	2215-2227	non-nicotine	_	
14-30	2228-2235	factors	_	
14-31	2235-2236	.	_	

#Text=These findings highlight that smoking addiction is associated with brain function changes.
15-1	2237-2242	These	_	
15-2	2243-2251	findings	_	
15-3	2252-2261	highlight	_	
15-4	2262-2266	that	_	
15-5	2267-2274	smoking	_	
15-6	2275-2284	addiction	_	
15-7	2285-2287	is	_	
15-8	2288-2298	associated	_	
15-9	2299-2303	with	_	
15-10	2304-2309	brain	_	
15-11	2310-2318	function	_	
15-12	2319-2326	changes	_	
15-13	2326-2327	.	_	

#Text=In the past several years, resting-state functional magnetic resonance imaging (rs-fMRI) has been increasingly used for studying neural activity in the brain.
16-1	2328-2330	In	_	
16-2	2331-2334	the	_	
16-3	2335-2339	past	_	
16-4	2340-2347	several	_	
16-5	2348-2353	years	_	
16-6	2353-2354	,	_	
16-7	2355-2368	resting-state	_	
16-8	2369-2379	functional	_	
16-9	2380-2388	magnetic	_	
16-10	2389-2398	resonance	_	
16-11	2399-2406	imaging	_	
16-12	2407-2408	(	_	
16-13	2408-2415	rs-fMRI	_	
16-14	2415-2416	)	_	
16-15	2417-2420	has	_	
16-16	2421-2425	been	_	
16-17	2426-2438	increasingly	_	
16-18	2439-2443	used	_	
16-19	2444-2447	for	_	
16-20	2448-2456	studying	_	
16-21	2457-2463	neural	_	
16-22	2464-2472	activity	_	
16-23	2473-2475	in	_	
16-24	2476-2479	the	_	
16-25	2480-2485	brain	_	
16-26	2485-2486	.	_	

#Text=This non-invasive imaging technique offers unbiased analysis of the region-to-region interactions and voxel-by-voxel neural activity at the functional level based on the rudimentary and intrinsic activity of the resting brain.
17-1	2487-2491	This	_	
17-2	2492-2504	non-invasive	_	
17-3	2505-2512	imaging	_	
17-4	2513-2522	technique	_	
17-5	2523-2529	offers	_	
17-6	2530-2538	unbiased	_	
17-7	2539-2547	analysis	_	
17-8	2548-2550	of	_	
17-9	2551-2554	the	_	
17-10	2555-2571	region-to-region	_	
17-11	2572-2584	interactions	_	
17-12	2585-2588	and	_	
17-13	2589-2603	voxel-by-voxel	_	
17-14	2604-2610	neural	_	
17-15	2611-2619	activity	_	
17-16	2620-2622	at	_	
17-17	2623-2626	the	_	
17-18	2627-2637	functional	_	
17-19	2638-2643	level	_	
17-20	2644-2649	based	_	
17-21	2650-2652	on	_	
17-22	2653-2656	the	_	
17-23	2657-2668	rudimentary	_	
17-24	2669-2672	and	_	
17-25	2673-2682	intrinsic	_	
17-26	2683-2691	activity	_	
17-27	2692-2694	of	_	
17-28	2695-2698	the	_	
17-29	2699-2706	resting	_	
17-30	2707-2712	brain	_	
17-31	2712-2713	.	_	

#Text=The technology has been widely applied for investigating the brain function and its changes caused by diseases.
18-1	2714-2717	The	_	
18-2	2718-2728	technology	_	
18-3	2729-2732	has	_	
18-4	2733-2737	been	_	
18-5	2738-2744	widely	_	
18-6	2745-2752	applied	_	
18-7	2753-2756	for	_	
18-8	2757-2770	investigating	_	
18-9	2771-2774	the	_	
18-10	2775-2780	brain	_	
18-11	2781-2789	function	_	
18-12	2790-2793	and	_	
18-13	2794-2797	its	_	
18-14	2798-2805	changes	_	
18-15	2806-2812	caused	_	
18-16	2813-2815	by	_	
18-17	2816-2824	diseases	_	
18-18	2824-2825	.	_	

#Text=Regional homogeneity (ReHo) is an important research method for rs-fMRI.
19-1	2826-2834	Regional	_	
19-2	2835-2846	homogeneity	_	
19-3	2847-2848	(	_	
19-4	2848-2852	ReHo	_	
19-5	2852-2853	)	_	
19-6	2854-2856	is	_	
19-7	2857-2859	an	_	
19-8	2860-2869	important	_	
19-9	2870-2878	research	_	
19-10	2879-2885	method	_	
19-11	2886-2889	for	_	
19-12	2890-2897	rs-fMRI	_	
19-13	2897-2898	.	_	

#Text=The method reflects the local temporal homogeneity of the regional blood oxygen level-dependent signal and serves as a complement for brain neural activity in resting state.
20-1	2899-2902	The	_	
20-2	2903-2909	method	_	
20-3	2910-2918	reflects	_	
20-4	2919-2922	the	_	
20-5	2923-2928	local	_	
20-6	2929-2937	temporal	_	
20-7	2938-2949	homogeneity	_	
20-8	2950-2952	of	_	
20-9	2953-2956	the	_	
20-10	2957-2965	regional	_	
20-11	2966-2971	blood	_	
20-12	2972-2978	oxygen	_	
20-13	2979-2994	level-dependent	_	
20-14	2995-3001	signal	_	
20-15	3002-3005	and	_	
20-16	3006-3012	serves	_	
20-17	3013-3015	as	_	
20-18	3016-3017	a	_	
20-19	3018-3028	complement	_	
20-20	3029-3032	for	_	
20-21	3033-3038	brain	_	
20-22	3039-3045	neural	_	
20-23	3046-3054	activity	_	
20-24	3055-3057	in	_	
20-25	3058-3065	resting	_	
20-26	3066-3071	state	_	
20-27	3071-3072	.	_	

#Text=The change in the ReHo values in the smoking cessation process has been extensively investigated.
21-1	3073-3076	The	_	
21-2	3077-3083	change	_	
21-3	3084-3086	in	_	
21-4	3087-3090	the	_	
21-5	3091-3095	ReHo	_	
21-6	3096-3102	values	_	
21-7	3103-3105	in	_	
21-8	3106-3109	the	_	
21-9	3110-3117	smoking	_	
21-10	3118-3127	cessation	_	
21-11	3128-3135	process	_	
21-12	3136-3139	has	_	
21-13	3140-3144	been	_	
21-14	3145-3156	extensively	_	
21-15	3157-3169	investigated	_	
21-16	3169-3170	.	_	

#Text=Yu et al. used ReHo combined with fMRI to investigate the spontaneous neural activity in the resting state of heavy smokers; however, they did not analyze the relation between the ReHo values and the clinical characteristics of the participants.
22-1	3171-3173	Yu	_	
22-2	3174-3176	et	_	
22-3	3177-3179	al	_	
22-4	3179-3180	.	_	
22-5	3181-3185	used	_	
22-6	3186-3190	ReHo	_	
22-7	3191-3199	combined	_	
22-8	3200-3204	with	_	
22-9	3205-3209	fMRI	_	
22-10	3210-3212	to	_	
22-11	3213-3224	investigate	_	
22-12	3225-3228	the	_	
22-13	3229-3240	spontaneous	_	
22-14	3241-3247	neural	_	
22-15	3248-3256	activity	_	
22-16	3257-3259	in	_	
22-17	3260-3263	the	_	
22-18	3264-3271	resting	_	
22-19	3272-3277	state	_	
22-20	3278-3280	of	_	
22-21	3281-3286	heavy	_	
22-22	3287-3294	smokers	_	
22-23	3294-3295	;	_	
22-24	3296-3303	however	_	
22-25	3303-3304	,	_	
22-26	3305-3309	they	_	
22-27	3310-3313	did	_	
22-28	3314-3317	not	_	
22-29	3318-3325	analyze	_	
22-30	3326-3329	the	_	
22-31	3330-3338	relation	_	
22-32	3339-3346	between	_	
22-33	3347-3350	the	_	
22-34	3351-3355	ReHo	_	
22-35	3356-3362	values	_	
22-36	3363-3366	and	_	
22-37	3367-3370	the	_	
22-38	3371-3379	clinical	_	
22-39	3380-3395	characteristics	_	
22-40	3396-3398	of	_	
22-41	3399-3402	the	_	
22-42	3403-3415	participants	_	
22-43	3415-3416	.	_	

#Text=The changes in the local synchronization of spontaneous fMRI signals that occur in nicotine addicts during the resting state are rarely explored, as well as the relation between these changes and the clinical characteristics of smokers.
23-1	3417-3420	The	_	
23-2	3421-3428	changes	_	
23-3	3429-3431	in	_	
23-4	3432-3435	the	_	
23-5	3436-3441	local	_	
23-6	3442-3457	synchronization	_	
23-7	3458-3460	of	_	
23-8	3461-3472	spontaneous	_	
23-9	3473-3477	fMRI	_	
23-10	3478-3485	signals	_	
23-11	3486-3490	that	_	
23-12	3491-3496	occur	_	
23-13	3497-3499	in	_	
23-14	3500-3508	nicotine	_	
23-15	3509-3516	addicts	_	
23-16	3517-3523	during	_	
23-17	3524-3527	the	_	
23-18	3528-3535	resting	_	
23-19	3536-3541	state	_	
23-20	3542-3545	are	_	
23-21	3546-3552	rarely	_	
23-22	3553-3561	explored	_	
23-23	3561-3562	,	_	
23-24	3563-3565	as	_	
23-25	3566-3570	well	_	
23-26	3571-3573	as	_	
23-27	3574-3577	the	_	
23-28	3578-3586	relation	_	
23-29	3587-3594	between	_	
23-30	3595-3600	these	_	
23-31	3601-3608	changes	_	
23-32	3609-3612	and	_	
23-33	3613-3616	the	_	
23-34	3617-3625	clinical	_	
23-35	3626-3641	characteristics	_	
23-36	3642-3644	of	_	
23-37	3645-3652	smokers	_	
23-38	3652-3653	.	_	

#Text=Fagerstrom Test for Nicotine Dependence (FTND) is an important index for the clinical evaluation of a smoker’s dependence on nicotine addiction; this index has been widely used in clinical treatment and research on nicotine addiction.
24-1	3654-3664	Fagerstrom	_	
24-2	3665-3669	Test	_	
24-3	3670-3673	for	_	
24-4	3674-3682	Nicotine	_	
24-5	3683-3693	Dependence	_	
24-6	3694-3695	(	_	
24-7	3695-3699	FTND	_	
24-8	3699-3700	)	_	
24-9	3701-3703	is	_	
24-10	3704-3706	an	_	
24-11	3707-3716	important	_	
24-12	3717-3722	index	_	
24-13	3723-3726	for	_	
24-14	3727-3730	the	_	
24-15	3731-3739	clinical	_	
24-16	3740-3750	evaluation	_	
24-17	3751-3753	of	_	
24-18	3754-3755	a	_	
24-19	3756-3762	smoker	_	
24-20	3762-3763	’	_	
24-21	3763-3764	s	_	
24-22	3765-3775	dependence	_	
24-23	3776-3778	on	_	
24-24	3779-3787	nicotine	_	
24-25	3788-3797	addiction	_	
24-26	3797-3798	;	_	
24-27	3799-3803	this	_	
24-28	3804-3809	index	_	
24-29	3810-3813	has	_	
24-30	3814-3818	been	_	
24-31	3819-3825	widely	_	
24-32	3826-3830	used	_	
24-33	3831-3833	in	_	
24-34	3834-3842	clinical	_	
24-35	3843-3852	treatment	_	
24-36	3853-3856	and	_	
24-37	3857-3865	research	_	
24-38	3866-3868	on	_	
24-39	3869-3877	nicotine	_	
24-40	3878-3887	addiction	_	
24-41	3887-3888	.	_	

#Text=In the present study, we hypothesized that the ReHo values of resting-state brain activity would be different between the smokers and the controls, and that the mechanism was related to the FTND scores.
25-1	3889-3891	In	_	
25-2	3892-3895	the	_	
25-3	3896-3903	present	_	
25-4	3904-3909	study	_	
25-5	3909-3910	,	_	
25-6	3911-3913	we	_	
25-7	3914-3926	hypothesized	_	
25-8	3927-3931	that	_	
25-9	3932-3935	the	_	
25-10	3936-3940	ReHo	_	
25-11	3941-3947	values	_	
25-12	3948-3950	of	_	
25-13	3951-3964	resting-state	_	
25-14	3965-3970	brain	_	
25-15	3971-3979	activity	_	
25-16	3980-3985	would	_	
25-17	3986-3988	be	_	
25-18	3989-3998	different	_	
25-19	3999-4006	between	_	
25-20	4007-4010	the	_	
25-21	4011-4018	smokers	_	
25-22	4019-4022	and	_	
25-23	4023-4026	the	_	
25-24	4027-4035	controls	_	
25-25	4035-4036	,	_	
25-26	4037-4040	and	_	
25-27	4041-4045	that	_	
25-28	4046-4049	the	_	
25-29	4050-4059	mechanism	_	
25-30	4060-4063	was	_	
25-31	4064-4071	related	_	
25-32	4072-4074	to	_	
25-33	4075-4078	the	_	
25-34	4079-4083	FTND	_	
25-35	4084-4090	scores	_	
25-36	4090-4091	.	_	

#Text=The present study aimed to explore the objective biomarker for nicotine dependence evaluation using rs-fMRI.
26-1	4092-4095	The	_	
26-2	4096-4103	present	_	
26-3	4104-4109	study	_	
26-4	4110-4115	aimed	_	
26-5	4116-4118	to	_	
26-6	4119-4126	explore	_	
26-7	4127-4130	the	_	
26-8	4131-4140	objective	_	
26-9	4141-4150	biomarker	_	
26-10	4151-4154	for	_	
26-11	4155-4163	nicotine	_	
26-12	4164-4174	dependence	_	
26-13	4175-4185	evaluation	_	
26-14	4186-4191	using	_	
26-15	4192-4199	rs-fMRI	_	
26-16	4199-4200	.	_	

#Text=Materials and Methods
#Text=Participants
#Text=The study was approved by the Ethics Committee of Affiliated Hospital of Guilin Medical University (Guilin, Guangxi, China).
27-1	4201-4210	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[9]	
27-2	4211-4214	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[9]	
27-3	4215-4222	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[9]	
27-4	4223-4235	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-5	4236-4239	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-6	4240-4245	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-7	4246-4249	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-8	4250-4258	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-9	4259-4261	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-10	4262-4265	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-11	4266-4272	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-12	4273-4282	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-13	4283-4285	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-14	4286-4296	Affiliated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-15	4297-4305	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-16	4306-4308	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-17	4309-4315	Guilin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-18	4316-4323	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-19	4324-4334	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-20	4335-4336	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-21	4336-4342	Guilin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-22	4342-4343	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-23	4344-4351	Guangxi	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-24	4351-4352	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-25	4353-4358	China	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-26	4358-4359	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
27-27	4359-4360	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=A total of 14 smokers and 11 non-smoking controls were recruited for this study.
28-1	4361-4362	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-2	4363-4368	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-3	4369-4371	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-4	4372-4374	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-5	4375-4382	smokers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[11]	
28-6	4383-4386	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-7	4387-4389	11	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-8	4390-4401	non-smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
28-9	4402-4410	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
28-10	4411-4415	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-11	4416-4425	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-12	4426-4429	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-13	4430-4434	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-14	4435-4440	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-15	4440-4441	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=All the participants signed consents to the experiment.
29-1	4442-4445	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-2	4446-4449	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-3	4450-4462	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-4	4463-4469	signed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-5	4470-4478	consents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-6	4479-4481	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-7	4482-4485	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-8	4486-4496	experiment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
29-9	4496-4497	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=The demographic and clinical data of subjects are summarized in Table 1.
30-1	4498-4501	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
30-2	4502-4513	demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
30-3	4514-4517	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
30-4	4518-4526	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
30-5	4527-4531	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
30-6	4532-4534	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
30-7	4535-4543	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
30-8	4544-4547	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
30-9	4548-4558	summarized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
30-10	4559-4561	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
30-11	4562-4567	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
30-12	4568-4569	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
30-13	4569-4570	.	_	

#Text=All participants were healthy males, received 12 years of education or longer, right-handed, showed no contraindications for MRI check, and exhibited no brain structural abnormality.
31-1	4571-4574	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-2	4575-4587	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-3	4588-4592	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-4	4593-4600	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-5	4601-4606	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-6	4606-4607	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-7	4608-4616	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-8	4617-4619	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-9	4620-4625	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-10	4626-4628	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-11	4629-4638	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-12	4639-4641	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-13	4642-4648	longer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-14	4648-4649	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-15	4650-4662	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-16	4662-4663	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-17	4664-4670	showed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-18	4671-4673	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-19	4674-4691	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-20	4692-4695	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-21	4696-4699	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[14]	
31-22	4700-4705	check	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-23	4705-4706	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-24	4707-4710	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-25	4711-4720	exhibited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-26	4721-4723	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-27	4724-4729	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-28	4730-4740	structural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-29	4741-4752	abnormality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-30	4752-4753	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Demographic and clinical characteristics of participants in this study.
32-1	4754-4765	Demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-2	4766-4769	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-3	4770-4778	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-4	4779-4794	characteristics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-5	4795-4797	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-6	4798-4810	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-7	4811-4813	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-8	4814-4818	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-9	4819-4824	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-10	4824-4825	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Smokers\tControls\tp-Value\t \tCharacteristics\tn = 14,M\tn = 11,M\t--\t \tAge(year)\t34.0±11.7\t34.5± 11.0\t0.907a\t \tEducation(years)\t16.6±2.7\t17.4±3.0\t0.537a\t \tFTND\t5.1±1.5\t--\t--\t \t
#Text=a The p-value for the difference between the two groups was obtained by two-sample t-test.
33-1	4827-4834	Smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
33-2	4835-4843	Controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
33-3	4844-4851	p-Value	_	
33-4	4854-4869	Characteristics	_	
33-5	4870-4871	n	_	
33-6	4872-4873	=	_	
33-7	4874-4876	14	_	
33-8	4876-4877	,	_	
33-9	4877-4878	M	_	
33-10	4879-4880	n	_	
33-11	4881-4882	=	_	
33-12	4883-4885	11	_	
33-13	4885-4886	,	_	
33-14	4886-4887	M	_	
33-15	4888-4889	-	_	
33-16	4889-4890	-	_	
33-17	4893-4896	Age	_	
33-18	4896-4897	(	_	
33-19	4897-4901	year	_	
33-20	4901-4902	)	_	
33-21	4903-4907	34.0	_	
33-22	4907-4908	±	_	
33-23	4908-4912	11.7	_	
33-24	4913-4917	34.5	_	
33-25	4917-4918	±	_	
33-26	4919-4923	11.0	_	
33-27	4924-4930	0.907a	_	
33-28	4933-4942	Education	_	
33-29	4942-4943	(	_	
33-30	4943-4948	years	_	
33-31	4948-4949	)	_	
33-32	4950-4954	16.6	_	
33-33	4954-4955	±	_	
33-34	4955-4958	2.7	_	
33-35	4959-4963	17.4	_	
33-36	4963-4964	±	_	
33-37	4964-4967	3.0	_	
33-38	4968-4974	0.537a	_	
33-39	4977-4981	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence	
33-40	4982-4985	5.1	_	
33-41	4985-4986	±	_	
33-42	4986-4989	1.5	_	
33-43	4990-4991	-	_	
33-44	4991-4992	-	_	
33-45	4993-4994	-	_	
33-46	4994-4995	-	_	
33-47	4999-5000	a	_	
33-48	5001-5004	The	_	
33-49	5005-5012	p-value	_	
33-50	5013-5016	for	_	
33-51	5017-5020	the	_	
33-52	5021-5031	difference	_	
33-53	5032-5039	between	_	
33-54	5040-5043	the	_	
33-55	5044-5047	two	_	
33-56	5048-5054	groups	_	
33-57	5055-5058	was	_	
33-58	5059-5067	obtained	_	
33-59	5068-5070	by	_	
33-60	5071-5081	two-sample	_	
33-61	5082-5088	t-test	_	
33-62	5088-5089	.	_	

#Text=FTND: Fagerstrom Test for Nicotine Dependence.
34-1	5090-5094	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[15]	
34-2	5094-5095	:	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[15]	
34-3	5096-5106	Fagerstrom	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[15]	
34-4	5107-5111	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[15]	
34-5	5112-5115	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[15]	
34-6	5116-5124	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[15]	
34-7	5125-5135	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[15]	
34-8	5135-5136	.	_	

#Text=M: Male
#Text=All smokers in the study were diagnosed based on the Diagnostic and Statistical Manual of Mental Disorders-IV, and they were smoking more than 10 cigarettes per day for 5 years or longer.
35-1	5137-5138	M	_	
35-2	5138-5139	:	_	
35-3	5140-5144	Male	_	
35-4	5145-5148	All	_	
35-5	5149-5156	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
35-6	5157-5159	in	_	
35-7	5160-5163	the	_	
35-8	5164-5169	study	_	
35-9	5170-5174	were	_	
35-10	5175-5184	diagnosed	_	
35-11	5185-5190	based	_	
35-12	5191-5193	on	_	
35-13	5194-5197	the	_	
35-14	5198-5208	Diagnostic	_	
35-15	5209-5212	and	_	
35-16	5213-5224	Statistical	_	
35-17	5225-5231	Manual	_	
35-18	5232-5234	of	_	
35-19	5235-5241	Mental	_	
35-20	5242-5254	Disorders-IV	_	
35-21	5254-5255	,	_	
35-22	5256-5259	and	_	
35-23	5260-5264	they	_	
35-24	5265-5269	were	_	
35-25	5270-5277	smoking	_	
35-26	5278-5282	more	_	
35-27	5283-5287	than	_	
35-28	5288-5290	10	_	
35-29	5291-5301	cigarettes	_	
35-30	5302-5305	per	_	
35-31	5306-5309	day	_	
35-32	5310-5313	for	_	
35-33	5314-5315	5	_	
35-34	5316-5321	years	_	
35-35	5322-5324	or	_	
35-36	5325-5331	longer	_	
35-37	5331-5332	.	_	

#Text=The smoking participants had no marijuana, heroin, alcohol, and other drug addiction.
36-1	5333-5336	The	_	
36-2	5337-5344	smoking	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[16]	
36-3	5345-5357	participants	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[16]	
36-4	5358-5361	had	_	
36-5	5362-5364	no	_	
36-6	5365-5374	marijuana	_	
36-7	5374-5375	,	_	
36-8	5376-5382	heroin	_	
36-9	5382-5383	,	_	
36-10	5384-5391	alcohol	_	
36-11	5391-5392	,	_	
36-12	5393-5396	and	_	
36-13	5397-5402	other	_	
36-14	5403-5407	drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[17]	
36-15	5408-5417	addiction	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[17]	
36-16	5417-5418	.	_	

#Text=They had no previous epilepsy, family history of epilepsy, and other psychiatric disorders.
37-1	5419-5423	They	_	
37-2	5424-5427	had	_	
37-3	5428-5430	no	_	
37-4	5431-5439	previous	_	
37-5	5440-5448	epilepsy	_	
37-6	5448-5449	,	_	
37-7	5450-5456	family	_	
37-8	5457-5464	history	_	
37-9	5465-5467	of	_	
37-10	5468-5476	epilepsy	_	
37-11	5476-5477	,	_	
37-12	5478-5481	and	_	
37-13	5482-5487	other	_	
37-14	5488-5499	psychiatric	_	
37-15	5500-5509	disorders	_	
37-16	5509-5510	.	_	

#Text=All smokers were tested by FTND.
38-1	5511-5514	All	_	
38-2	5515-5522	smokers	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
38-3	5523-5527	were	_	
38-4	5528-5534	tested	_	
38-5	5535-5537	by	_	
38-6	5538-5542	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence	
38-7	5542-5543	.	_	

#Text=Data Acquisition
#Text=MRI data were collected with a 3T Siemens Verio MRI scanner at the Affiliated Hospital of Guilin Medical University using a 12-channel head coil.
39-1	5544-5548	Data	_	
39-2	5549-5560	Acquisition	_	
39-3	5561-5564	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
39-4	5565-5569	data	_	
39-5	5570-5574	were	_	
39-6	5575-5584	collected	_	
39-7	5585-5589	with	_	
39-8	5590-5591	a	_	
39-9	5592-5594	3T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[18]	
39-10	5595-5602	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[18]	
39-11	5603-5608	Verio	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[18]	
39-12	5609-5612	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[18]	
39-13	5613-5620	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[18]	
39-14	5621-5623	at	_	
39-15	5624-5627	the	_	
39-16	5628-5638	Affiliated	_	
39-17	5639-5647	Hospital	_	
39-18	5648-5650	of	_	
39-19	5651-5657	Guilin	_	
39-20	5658-5665	Medical	_	
39-21	5666-5676	University	_	
39-22	5677-5682	using	_	
39-23	5683-5684	a	_	
39-24	5685-5687	12	_	
39-25	5687-5688	-	_	
39-26	5688-5695	channel	_	
39-27	5696-5700	head	_	
39-28	5701-5705	coil	_	
39-29	5705-5706	.	_	

#Text=Participants laid in the scanner in the supine position.
40-1	5707-5719	Participants	_	
40-2	5720-5724	laid	_	
40-3	5725-5727	in	_	
40-4	5728-5731	the	_	
40-5	5732-5739	scanner	_	
40-6	5740-5742	in	_	
40-7	5743-5746	the	_	
40-8	5747-5753	supine	_	
40-9	5754-5762	position	_	
40-10	5762-5763	.	_	

#Text=Cushions and forehead straps were used to immobilize the head to minimize movement.
41-1	5764-5772	Cushions	_	
41-2	5773-5776	and	_	
41-3	5777-5785	forehead	_	
41-4	5786-5792	straps	_	
41-5	5793-5797	were	_	
41-6	5798-5802	used	_	
41-7	5803-5805	to	_	
41-8	5806-5816	immobilize	_	
41-9	5817-5820	the	_	
41-10	5821-5825	head	_	
41-11	5826-5828	to	_	
41-12	5829-5837	minimize	_	
41-13	5838-5846	movement	_	
41-14	5846-5847	.	_	

#Text=During rs-fMRI data acquisition, participants were instructed to rest with their eyes close.
42-1	5848-5854	During	_	
42-2	5855-5862	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	
42-3	5863-5867	data	_	
42-4	5868-5879	acquisition	_	
42-5	5879-5880	,	_	
42-6	5881-5893	participants	_	
42-7	5894-5898	were	_	
42-8	5899-5909	instructed	_	
42-9	5910-5912	to	_	
42-10	5913-5917	rest	_	
42-11	5918-5922	with	_	
42-12	5923-5928	their	_	
42-13	5929-5933	eyes	_	
42-14	5934-5939	close	_	
42-15	5939-5940	.	_	

#Text=Functional images were acquired using a single-shot gradient echo-echo planar imaging sequence.
43-1	5941-5951	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
43-2	5952-5958	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
43-3	5959-5963	were	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
43-4	5964-5972	acquired	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
43-5	5973-5978	using	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
43-6	5979-5980	a	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
43-7	5981-5992	single-shot	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
43-8	5993-6001	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
43-9	6002-6011	echo-echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
43-10	6012-6018	planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
43-11	6019-6026	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
43-12	6027-6035	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[19]	
43-13	6035-6036	.	_	

#Text=The imaging parameters were as follows: field of view (FOV) = 22 cm × 22 cm, slices = 43, slice thickness = 3.2 mm, no slice gap, repetition time (TR) = 2000 ms, echo time (TE) = 30 ms, flip angle (FA) = 90 with nominal resolution = 3.4 mm × 3.4 mm × 3.2 mm and matrix = 64 × 64.
44-1	6037-6040	The	_	
44-2	6041-6048	imaging	_	
44-3	6049-6059	parameters	_	
44-4	6060-6064	were	_	
44-5	6065-6067	as	_	
44-6	6068-6075	follows	_	
44-7	6075-6076	:	_	
44-8	6077-6082	field	_	
44-9	6083-6085	of	_	
44-10	6086-6090	view	_	
44-11	6091-6092	(	_	
44-12	6092-6095	FOV	_	
44-13	6095-6096	)	_	
44-14	6097-6098	=	_	
44-15	6099-6101	22	_	
44-16	6102-6104	cm	_	
44-17	6105-6106	×	_	
44-18	6107-6109	22	_	
44-19	6110-6112	cm	_	
44-20	6112-6113	,	_	
44-21	6114-6120	slices	_	
44-22	6121-6122	=	_	
44-23	6123-6125	43	_	
44-24	6125-6126	,	_	
44-25	6127-6132	slice	_	
44-26	6133-6142	thickness	_	
44-27	6143-6144	=	_	
44-28	6145-6148	3.2	_	
44-29	6149-6151	mm	_	
44-30	6151-6152	,	_	
44-31	6153-6155	no	_	
44-32	6156-6161	slice	_	
44-33	6162-6165	gap	_	
44-34	6165-6166	,	_	
44-35	6167-6177	repetition	_	
44-36	6178-6182	time	_	
44-37	6183-6184	(	_	
44-38	6184-6186	TR	_	
44-39	6186-6187	)	_	
44-40	6188-6189	=	_	
44-41	6190-6194	2000	_	
44-42	6195-6197	ms	_	
44-43	6197-6198	,	_	
44-44	6199-6203	echo	_	
44-45	6204-6208	time	_	
44-46	6209-6210	(	_	
44-47	6210-6212	TE	_	
44-48	6212-6213	)	_	
44-49	6214-6215	=	_	
44-50	6216-6218	30	_	
44-51	6219-6221	ms	_	
44-52	6221-6222	,	_	
44-53	6223-6227	flip	_	
44-54	6228-6233	angle	_	
44-55	6234-6235	(	_	
44-56	6235-6237	FA	_	
44-57	6237-6238	)	_	
44-58	6239-6240	=	_	
44-59	6241-6243	90	_	
44-60	6244-6248	with	_	
44-61	6249-6256	nominal	_	
44-62	6257-6267	resolution	_	
44-63	6268-6269	=	_	
44-64	6270-6273	3.4	_	
44-65	6274-6276	mm	_	
44-66	6277-6278	×	_	
44-67	6279-6282	3.4	_	
44-68	6283-6285	mm	_	
44-69	6286-6287	×	_	
44-70	6288-6291	3.2	_	
44-71	6292-6294	mm	_	
44-72	6295-6298	and	_	
44-73	6299-6305	matrix	_	
44-74	6306-6307	=	_	
44-75	6308-6310	64	_	
44-76	6311-6312	×	_	
44-77	6313-6315	64	_	
44-78	6315-6316	.	_	

#Text=The scan time of each rs-fMRI was 480 s, and a total of 240 volumes were collected.
45-1	6317-6320	The	_	
45-2	6321-6325	scan	_	
45-3	6326-6330	time	_	
45-4	6331-6333	of	_	
45-5	6334-6338	each	_	
45-6	6339-6346	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	
45-7	6347-6350	was	_	
45-8	6351-6354	480	_	
45-9	6355-6356	s	_	
45-10	6356-6357	,	_	
45-11	6358-6361	and	_	
45-12	6362-6363	a	_	
45-13	6364-6369	total	_	
45-14	6370-6372	of	_	
45-15	6373-6376	240	_	
45-16	6377-6384	volumes	_	
45-17	6385-6389	were	_	
45-18	6390-6399	collected	_	
45-19	6399-6400	.	_	

#Text=Structural images were acquired using a three-dimensional magnetization- prepared rapid gradient-echo sequence with TR = 1900 ms, TE = 2.52 ms, FA = 8, matrix = 256 × 256, FOV = 25.6 cm × 25.6 cm, slice thickness = 1.0 mm, and no slice gap.
46-1	6401-6411	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[20]	
46-2	6412-6418	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[20]	
46-3	6419-6423	were	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[20]	
46-4	6424-6432	acquired	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[20]	
46-5	6433-6438	using	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[20]	
46-6	6439-6440	a	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[20]	
46-7	6441-6458	three-dimensional	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[20]	
46-8	6459-6472	magnetization	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[20]	
46-9	6472-6473	-	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[20]	
46-10	6474-6482	prepared	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[20]	
46-11	6483-6488	rapid	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[20]	
46-12	6489-6502	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[20]	
46-13	6503-6511	sequence	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[20]	
46-14	6512-6516	with	_	
46-15	6517-6519	TR	_	
46-16	6520-6521	=	_	
46-17	6522-6526	1900	_	
46-18	6527-6529	ms	_	
46-19	6529-6530	,	_	
46-20	6531-6533	TE	_	
46-21	6534-6535	=	_	
46-22	6536-6540	2.52	_	
46-23	6541-6543	ms	_	
46-24	6543-6544	,	_	
46-25	6545-6547	FA	_	
46-26	6548-6549	=	_	
46-27	6550-6551	8	_	
46-28	6551-6552	,	_	
46-29	6553-6559	matrix	_	
46-30	6560-6561	=	_	
46-31	6562-6565	256	_	
46-32	6566-6567	×	_	
46-33	6568-6571	256	_	
46-34	6571-6572	,	_	
46-35	6573-6576	FOV	_	
46-36	6577-6578	=	_	
46-37	6579-6583	25.6	_	
46-38	6584-6586	cm	_	
46-39	6587-6588	×	_	
46-40	6589-6593	25.6	_	
46-41	6594-6596	cm	_	
46-42	6596-6597	,	_	
46-43	6598-6603	slice	_	
46-44	6604-6613	thickness	_	
46-45	6614-6615	=	_	
46-46	6616-6619	1.0	_	
46-47	6620-6622	mm	_	
46-48	6622-6623	,	_	
46-49	6624-6627	and	_	
46-50	6628-6630	no	_	
46-51	6631-6636	slice	_	
46-52	6637-6640	gap	_	
46-53	6640-6641	.	_	

#Text=A total of 176 slices were used to cover the whole brain.
47-1	6642-6643	A	_	
47-2	6644-6649	total	_	
47-3	6650-6652	of	_	
47-4	6653-6656	176	_	
47-5	6657-6663	slices	_	
47-6	6664-6668	were	_	
47-7	6669-6673	used	_	
47-8	6674-6676	to	_	
47-9	6677-6682	cover	_	
47-10	6683-6686	the	_	
47-11	6687-6692	whole	_	
47-12	6693-6698	brain	_	
47-13	6698-6699	.	_	

#Text=Data Analysis
#Text=All rs-fMRI data were preprocessed using the software for Data Processing Assistant for Resting-State fMRI (DPARSF, http://www.restfmri.net/forum/DPARSF) based on Statistical Parametric Mapping (SPM8, http://www.fil.ion.ucl.ac.uk/spm) and Resting-state fMRI Data Analysis Toolkit (REST, http://www.restfmri.net).
48-1	6700-6704	Data	_	
48-2	6705-6713	Analysis	_	
48-3	6714-6717	All	_	
48-4	6718-6725	rs-fMRI	_	
48-5	6726-6730	data	_	
48-6	6731-6735	were	_	
48-7	6736-6748	preprocessed	_	
48-8	6749-6754	using	_	
48-9	6755-6758	the	_	
48-10	6759-6767	software	_	
48-11	6768-6771	for	_	
48-12	6772-6776	Data	_	
48-13	6777-6787	Processing	_	
48-14	6788-6797	Assistant	_	
48-15	6798-6801	for	_	
48-16	6802-6815	Resting-State	_	
48-17	6816-6820	fMRI	_	
48-18	6821-6822	(	_	
48-19	6822-6828	DPARSF	_	
48-20	6828-6829	,	_	
48-21	6830-6834	http	_	
48-22	6834-6835	:	_	
48-23	6835-6836	/	_	
48-24	6836-6837	/	_	
48-25	6837-6853	www.restfmri.net	_	
48-26	6853-6854	/	_	
48-27	6854-6859	forum	_	
48-28	6859-6860	/	_	
48-29	6860-6866	DPARSF	_	
48-30	6866-6867	)	_	
48-31	6868-6873	based	_	
48-32	6874-6876	on	_	
48-33	6877-6888	Statistical	_	
48-34	6889-6899	Parametric	_	
48-35	6900-6907	Mapping	_	
48-36	6908-6909	(	_	
48-37	6909-6913	SPM8	_	
48-38	6913-6914	,	_	
48-39	6915-6919	http	_	
48-40	6919-6920	:	_	
48-41	6920-6921	/	_	
48-42	6921-6922	/	_	
48-43	6922-6943	www.fil.ion.ucl.ac.uk	_	
48-44	6943-6944	/	_	
48-45	6944-6947	spm	_	
48-46	6947-6948	)	_	
48-47	6949-6952	and	_	
48-48	6953-6966	Resting-state	_	
48-49	6967-6971	fMRI	_	
48-50	6972-6976	Data	_	
48-51	6977-6985	Analysis	_	
48-52	6986-6993	Toolkit	_	
48-53	6994-6995	(	_	
48-54	6995-6999	REST	_	
48-55	6999-7000	,	_	
48-56	7001-7005	http	_	
48-57	7005-7006	:	_	
48-58	7006-7007	/	_	
48-59	7007-7008	/	_	
48-60	7008-7024	www.restfmri.net	_	
48-61	7024-7025	)	_	
48-62	7025-7026	.	_	

#Text=We converted the DICOM data to NIfTI format.
49-1	7027-7029	We	_	
49-2	7030-7039	converted	_	
49-3	7040-7043	the	_	
49-4	7044-7049	DICOM	_	
49-5	7050-7054	data	_	
49-6	7055-7057	to	_	
49-7	7058-7063	NIfTI	_	
49-8	7064-7070	format	_	
49-9	7070-7071	.	_	

#Text=The first 10 volumes of each time series of echo-planar images were discarded to prevent the effect of the un-equilibrium of tissue magnetization that may introduce artifacts in the signal.
50-1	7072-7075	The	_	
50-2	7076-7081	first	_	
50-3	7082-7084	10	_	
50-4	7085-7092	volumes	_	
50-5	7093-7095	of	_	
50-6	7096-7100	each	_	
50-7	7101-7105	time	_	
50-8	7106-7112	series	_	
50-9	7113-7115	of	_	
50-10	7116-7127	echo-planar	_	
50-11	7128-7134	images	_	
50-12	7135-7139	were	_	
50-13	7140-7149	discarded	_	
50-14	7150-7152	to	_	
50-15	7153-7160	prevent	_	
50-16	7161-7164	the	_	
50-17	7165-7171	effect	_	
50-18	7172-7174	of	_	
50-19	7175-7178	the	_	
50-20	7179-7193	un-equilibrium	_	
50-21	7194-7196	of	_	
50-22	7197-7203	tissue	_	
50-23	7204-7217	magnetization	_	
50-24	7218-7222	that	_	
50-25	7223-7226	may	_	
50-26	7227-7236	introduce	_	
50-27	7237-7246	artifacts	_	
50-28	7247-7249	in	_	
50-29	7250-7253	the	_	
50-30	7254-7260	signal	_	
50-31	7260-7261	.	_	

#Text=The remaining 230 time points of each time course image series were used for analysis.
51-1	7262-7265	The	_	
51-2	7266-7275	remaining	_	
51-3	7276-7279	230	_	
51-4	7280-7284	time	_	
51-5	7285-7291	points	_	
51-6	7292-7294	of	_	
51-7	7295-7299	each	_	
51-8	7300-7304	time	_	
51-9	7305-7311	course	_	
51-10	7312-7317	image	_	
51-11	7318-7324	series	_	
51-12	7325-7329	were	_	
51-13	7330-7334	used	_	
51-14	7335-7338	for	_	
51-15	7339-7347	analysis	_	
51-16	7347-7348	.	_	

#Text=The selected time course images were subsequently corrected for slice timing and realigned to the image of the first time point for the correction of the rigid-body head movement.
52-1	7349-7352	The	_	
52-2	7353-7361	selected	_	
52-3	7362-7366	time	_	
52-4	7367-7373	course	_	
52-5	7374-7380	images	_	
52-6	7381-7385	were	_	
52-7	7386-7398	subsequently	_	
52-8	7399-7408	corrected	_	
52-9	7409-7412	for	_	
52-10	7413-7418	slice	_	
52-11	7419-7425	timing	_	
52-12	7426-7429	and	_	
52-13	7430-7439	realigned	_	
52-14	7440-7442	to	_	
52-15	7443-7446	the	_	
52-16	7447-7452	image	_	
52-17	7453-7455	of	_	
52-18	7456-7459	the	_	
52-19	7460-7465	first	_	
52-20	7466-7470	time	_	
52-21	7471-7476	point	_	
52-22	7477-7480	for	_	
52-23	7481-7484	the	_	
52-24	7485-7495	correction	_	
52-25	7496-7498	of	_	
52-26	7499-7502	the	_	
52-27	7503-7513	rigid-body	_	
52-28	7514-7518	head	_	
52-29	7519-7527	movement	_	
52-30	7527-7528	.	_	

#Text=At any time course, data exhibiting distortion from the movement larger than 1.5 mm and rotation larger than 1.5° were discarded.
53-1	7529-7531	At	_	
53-2	7532-7535	any	_	
53-3	7536-7540	time	_	
53-4	7541-7547	course	_	
53-5	7547-7548	,	_	
53-6	7549-7553	data	_	
53-7	7554-7564	exhibiting	_	
53-8	7565-7575	distortion	_	
53-9	7576-7580	from	_	
53-10	7581-7584	the	_	
53-11	7585-7593	movement	_	
53-12	7594-7600	larger	_	
53-13	7601-7605	than	_	
53-14	7606-7609	1.5	_	
53-15	7610-7612	mm	_	
53-16	7613-7616	and	_	
53-17	7617-7625	rotation	_	
53-18	7626-7632	larger	_	
53-19	7633-7637	than	_	
53-20	7638-7641	1.5	_	
53-21	7641-7642	°	_	
53-22	7643-7647	were	_	
53-23	7648-7657	discarded	_	
53-24	7657-7658	.	_	

#Text=The time course images (3 mm × 3 mm × 3 mm) were then spatially normalized into the standard Montreal Neurological Institute space.
54-1	7659-7662	The	_	
54-2	7663-7667	time	_	
54-3	7668-7674	course	_	
54-4	7675-7681	images	_	
54-5	7682-7683	(	_	
54-6	7683-7684	3	_	
54-7	7685-7687	mm	_	
54-8	7688-7689	×	_	
54-9	7690-7691	3	_	
54-10	7692-7694	mm	_	
54-11	7695-7696	×	_	
54-12	7697-7698	3	_	
54-13	7699-7701	mm	_	
54-14	7701-7702	)	_	
54-15	7703-7707	were	_	
54-16	7708-7712	then	_	
54-17	7713-7722	spatially	_	
54-18	7723-7733	normalized	_	
54-19	7734-7738	into	_	
54-20	7739-7742	the	_	
54-21	7743-7751	standard	_	
54-22	7752-7760	Montreal	_	
54-23	7761-7773	Neurological	_	
54-24	7774-7783	Institute	_	
54-25	7784-7789	space	_	
54-26	7789-7790	.	_	

#Text=Data were temporal band-pass filtered (0.01–0.08 Hz) to reduce the effects of low-frequency drift and physiological high-frequency noise.
55-1	7791-7795	Data	_	
55-2	7796-7800	were	_	
55-3	7801-7809	temporal	_	
55-4	7810-7819	band-pass	_	
55-5	7820-7828	filtered	_	
55-6	7829-7830	(	_	
55-7	7830-7834	0.01	_	
55-8	7834-7835	–	_	
55-9	7835-7839	0.08	_	
55-10	7840-7842	Hz	_	
55-11	7842-7843	)	_	
55-12	7844-7846	to	_	
55-13	7847-7853	reduce	_	
55-14	7854-7857	the	_	
55-15	7858-7865	effects	_	
55-16	7866-7868	of	_	
55-17	7869-7882	low-frequency	_	
55-18	7883-7888	drift	_	
55-19	7889-7892	and	_	
55-20	7893-7906	physiological	_	
55-21	7907-7921	high-frequency	_	
55-22	7922-7927	noise	_	
55-23	7927-7928	.	_	

#Text=The linear trend was also removed.
56-1	7929-7932	The	_	
56-2	7933-7939	linear	_	
56-3	7940-7945	trend	_	
56-4	7946-7949	was	_	
56-5	7950-7954	also	_	
56-6	7955-7962	removed	_	
56-7	7962-7963	.	_	

#Text=The ReHo analysis was performed with the REST toolkit.
57-1	7964-7967	The	_	
57-2	7968-7972	ReHo	_	
57-3	7973-7981	analysis	_	
57-4	7982-7985	was	_	
57-5	7986-7995	performed	_	
57-6	7996-8000	with	_	
57-7	8001-8004	the	_	
57-8	8005-8009	REST	_	
57-9	8010-8017	toolkit	_	
57-10	8017-8018	.	_	

#Text=The ReHo maps were generated for each subject by calculating the Kendall coefficient of concordance (KCC) of the time series of a given voxel.
58-1	8019-8022	The	_	
58-2	8023-8027	ReHo	_	
58-3	8028-8032	maps	_	
58-4	8033-8037	were	_	
58-5	8038-8047	generated	_	
58-6	8048-8051	for	_	
58-7	8052-8056	each	_	
58-8	8057-8064	subject	_	
58-9	8065-8067	by	_	
58-10	8068-8079	calculating	_	
58-11	8080-8083	the	_	
58-12	8084-8091	Kendall	_	
58-13	8092-8103	coefficient	_	
58-14	8104-8106	of	_	
58-15	8107-8118	concordance	_	
58-16	8119-8120	(	_	
58-17	8120-8123	KCC	_	
58-18	8123-8124	)	_	
58-19	8125-8127	of	_	
58-20	8128-8131	the	_	
58-21	8132-8136	time	_	
58-22	8137-8143	series	_	
58-23	8144-8146	of	_	
58-24	8147-8148	a	_	
58-25	8149-8154	given	_	
58-26	8155-8160	voxel	_	
58-27	8160-8161	.	_	

#Text=The KCC for each voxel in the brain was calculated voxel-wise by 27 voxels (one given voxel plus its adjacent 26 voxels).
59-1	8162-8165	The	_	
59-2	8166-8169	KCC	_	
59-3	8170-8173	for	_	
59-4	8174-8178	each	_	
59-5	8179-8184	voxel	_	
59-6	8185-8187	in	_	
59-7	8188-8191	the	_	
59-8	8192-8197	brain	_	
59-9	8198-8201	was	_	
59-10	8202-8212	calculated	_	
59-11	8213-8223	voxel-wise	_	
59-12	8224-8226	by	_	
59-13	8227-8229	27	_	
59-14	8230-8236	voxels	_	
59-15	8237-8238	(	_	
59-16	8238-8241	one	_	
59-17	8242-8247	given	_	
59-18	8248-8253	voxel	_	
59-19	8254-8258	plus	_	
59-20	8259-8262	its	_	
59-21	8263-8271	adjacent	_	
59-22	8272-8274	26	_	
59-23	8275-8281	voxels	_	
59-24	8281-8282	)	_	
59-25	8282-8283	.	_	

#Text=The standard ReHo value for each voxel is the KCC value of the voxel/the mean of the KCC values of the whole brain.
60-1	8284-8287	The	_	
60-2	8288-8296	standard	_	
60-3	8297-8301	ReHo	_	
60-4	8302-8307	value	_	
60-5	8308-8311	for	_	
60-6	8312-8316	each	_	
60-7	8317-8322	voxel	_	
60-8	8323-8325	is	_	
60-9	8326-8329	the	_	
60-10	8330-8333	KCC	_	
60-11	8334-8339	value	_	
60-12	8340-8342	of	_	
60-13	8343-8346	the	_	
60-14	8347-8352	voxel	_	
60-15	8352-8353	/	_	
60-16	8353-8356	the	_	
60-17	8357-8361	mean	_	
60-18	8362-8364	of	_	
60-19	8365-8368	the	_	
60-20	8369-8372	KCC	_	
60-21	8373-8379	values	_	
60-22	8380-8382	of	_	
60-23	8383-8386	the	_	
60-24	8387-8392	whole	_	
60-25	8393-8398	brain	_	
60-26	8398-8399	.	_	

#Text=Spatial smoothing was then performed on the standardized individual ReHo maps using an isotropic Gaussian filter with a Gaussian kernel of 6 mm and full-width at half maximum (FWHM).
61-1	8400-8407	Spatial	_	
61-2	8408-8417	smoothing	_	
61-3	8418-8421	was	_	
61-4	8422-8426	then	_	
61-5	8427-8436	performed	_	
61-6	8437-8439	on	_	
61-7	8440-8443	the	_	
61-8	8444-8456	standardized	_	
61-9	8457-8467	individual	_	
61-10	8468-8472	ReHo	_	
61-11	8473-8477	maps	_	
61-12	8478-8483	using	_	
61-13	8484-8486	an	_	
61-14	8487-8496	isotropic	_	
61-15	8497-8505	Gaussian	_	
61-16	8506-8512	filter	_	
61-17	8513-8517	with	_	
61-18	8518-8519	a	_	
61-19	8520-8528	Gaussian	_	
61-20	8529-8535	kernel	_	
61-21	8536-8538	of	_	
61-22	8539-8540	6	_	
61-23	8541-8543	mm	_	
61-24	8544-8547	and	_	
61-25	8548-8558	full-width	_	
61-26	8559-8561	at	_	
61-27	8562-8566	half	_	
61-28	8567-8574	maximum	_	
61-29	8575-8576	(	_	
61-30	8576-8580	FWHM	_	
61-31	8580-8581	)	_	
61-32	8581-8582	.	_	

#Text=Statistical Analysis
#Text=For the demographic and clinical data, two-sample t-tests were conducted to identify the difference in age and education between the smokers and the controls.
62-1	8583-8594	Statistical	_	
62-2	8595-8603	Analysis	_	
62-3	8604-8607	For	_	
62-4	8608-8611	the	_	
62-5	8612-8623	demographic	_	
62-6	8624-8627	and	_	
62-7	8628-8636	clinical	_	
62-8	8637-8641	data	_	
62-9	8641-8642	,	_	
62-10	8643-8653	two-sample	_	
62-11	8654-8661	t-tests	_	
62-12	8662-8666	were	_	
62-13	8667-8676	conducted	_	
62-14	8677-8679	to	_	
62-15	8680-8688	identify	_	
62-16	8689-8692	the	_	
62-17	8693-8703	difference	_	
62-18	8704-8706	in	_	
62-19	8707-8710	age	_	
62-20	8711-8714	and	_	
62-21	8715-8724	education	_	
62-22	8725-8732	between	_	
62-23	8733-8736	the	_	
62-24	8737-8744	smokers	_	
62-25	8745-8748	and	_	
62-26	8749-8752	the	_	
62-27	8753-8761	controls	_	
62-28	8761-8762	.	_	

#Text=The threshold for all statistical significance was set at p<0.05.
63-1	8763-8766	The	_	
63-2	8767-8776	threshold	_	
63-3	8777-8780	for	_	
63-4	8781-8784	all	_	
63-5	8785-8796	statistical	_	
63-6	8797-8809	significance	_	
63-7	8810-8813	was	_	
63-8	8814-8817	set	_	
63-9	8818-8820	at	_	
63-10	8821-8822	p	_	
63-11	8822-8823	<	_	
63-12	8823-8827	0.05	_	
63-13	8827-8828	.	_	

#Text=For ReHo, two-sample t-test was performed to examine the voxel-wise difference between the smokers and the controls by the REST toolbox.
64-1	8829-8832	For	_	
64-2	8833-8837	ReHo	_	
64-3	8837-8838	,	_	
64-4	8839-8849	two-sample	_	
64-5	8850-8856	t-test	_	
64-6	8857-8860	was	_	
64-7	8861-8870	performed	_	
64-8	8871-8873	to	_	
64-9	8874-8881	examine	_	
64-10	8882-8885	the	_	
64-11	8886-8896	voxel-wise	_	
64-12	8897-8907	difference	_	
64-13	8908-8915	between	_	
64-14	8916-8919	the	_	
64-15	8920-8927	smokers	_	
64-16	8928-8931	and	_	
64-17	8932-8935	the	_	
64-18	8936-8944	controls	_	
64-19	8945-8947	by	_	
64-20	8948-8951	the	_	
64-21	8952-8956	REST	_	
64-22	8957-8964	toolbox	_	
64-23	8964-8965	.	_	

#Text=Voxels with p<0.01 and cluster size >54 voxels were observed, which resulted in a corrected threshold of p<0.005 determined by AlphaSim (individual voxel P value = 0.01, FWHM = 6 mm, iterations = 1000, rmm = 5, with mask).
65-1	8966-8972	Voxels	_	
65-2	8973-8977	with	_	
65-3	8978-8979	p	_	
65-4	8979-8980	<	_	
65-5	8980-8984	0.01	_	
65-6	8985-8988	and	_	
65-7	8989-8996	cluster	_	
65-8	8997-9001	size	_	
65-9	9002-9003	>	_	
65-10	9003-9005	54	_	
65-11	9006-9012	voxels	_	
65-12	9013-9017	were	_	
65-13	9018-9026	observed	_	
65-14	9026-9027	,	_	
65-15	9028-9033	which	_	
65-16	9034-9042	resulted	_	
65-17	9043-9045	in	_	
65-18	9046-9047	a	_	
65-19	9048-9057	corrected	_	
65-20	9058-9067	threshold	_	
65-21	9068-9070	of	_	
65-22	9071-9072	p	_	
65-23	9072-9073	<	_	
65-24	9073-9078	0.005	_	
65-25	9079-9089	determined	_	
65-26	9090-9092	by	_	
65-27	9093-9101	AlphaSim	_	
65-28	9102-9103	(	_	
65-29	9103-9113	individual	_	
65-30	9114-9119	voxel	_	
65-31	9120-9121	P	_	
65-32	9122-9127	value	_	
65-33	9128-9129	=	_	
65-34	9130-9134	0.01	_	
65-35	9134-9135	,	_	
65-36	9136-9140	FWHM	_	
65-37	9141-9142	=	_	
65-38	9143-9144	6	_	
65-39	9145-9147	mm	_	
65-40	9147-9148	,	_	
65-41	9149-9159	iterations	_	
65-42	9160-9161	=	_	
65-43	9162-9166	1000	_	
65-44	9166-9167	,	_	
65-45	9168-9171	rmm	_	
65-46	9172-9173	=	_	
65-47	9174-9175	5	_	
65-48	9175-9176	,	_	
65-49	9177-9181	with	_	
65-50	9182-9186	mask	_	
65-51	9186-9187	)	_	
65-52	9187-9188	.	_	

#Text=These voxels were regarded as the regions of interest (ROI) showing significant difference between the two groups.
66-1	9189-9194	These	_	
66-2	9195-9201	voxels	_	
66-3	9202-9206	were	_	
66-4	9207-9215	regarded	_	
66-5	9216-9218	as	_	
66-6	9219-9222	the	_	
66-7	9223-9230	regions	_	
66-8	9231-9233	of	_	
66-9	9234-9242	interest	_	
66-10	9243-9244	(	_	
66-11	9244-9247	ROI	_	
66-12	9247-9248	)	_	
66-13	9249-9256	showing	_	
66-14	9257-9268	significant	_	
66-15	9269-9279	difference	_	
66-16	9280-9287	between	_	
66-17	9288-9291	the	_	
66-18	9292-9295	two	_	
66-19	9296-9302	groups	_	
66-20	9302-9303	.	_	

#Text=To further explore the brain region that may be related to the clinical variable of smokers, correlation analysis was performed between FTND and mean ReHo in a sphere with 5 mm radius centered on the location with the maximal t-value in the t-map in each ROI.
67-1	9304-9306	To	_	
67-2	9307-9314	further	_	
67-3	9315-9322	explore	_	
67-4	9323-9326	the	_	
67-5	9327-9332	brain	_	
67-6	9333-9339	region	_	
67-7	9340-9344	that	_	
67-8	9345-9348	may	_	
67-9	9349-9351	be	_	
67-10	9352-9359	related	_	
67-11	9360-9362	to	_	
67-12	9363-9366	the	_	
67-13	9367-9375	clinical	_	
67-14	9376-9384	variable	_	
67-15	9385-9387	of	_	
67-16	9388-9395	smokers	_	
67-17	9395-9396	,	_	
67-18	9397-9408	correlation	_	
67-19	9409-9417	analysis	_	
67-20	9418-9421	was	_	
67-21	9422-9431	performed	_	
67-22	9432-9439	between	_	
67-23	9440-9444	FTND	_	
67-24	9445-9448	and	_	
67-25	9449-9453	mean	_	
67-26	9454-9458	ReHo	_	
67-27	9459-9461	in	_	
67-28	9462-9463	a	_	
67-29	9464-9470	sphere	_	
67-30	9471-9475	with	_	
67-31	9476-9477	5	_	
67-32	9478-9480	mm	_	
67-33	9481-9487	radius	_	
67-34	9488-9496	centered	_	
67-35	9497-9499	on	_	
67-36	9500-9503	the	_	
67-37	9504-9512	location	_	
67-38	9513-9517	with	_	
67-39	9518-9521	the	_	
67-40	9522-9529	maximal	_	
67-41	9530-9537	t-value	_	
67-42	9538-9540	in	_	
67-43	9541-9544	the	_	
67-44	9545-9550	t-map	_	
67-45	9551-9553	in	_	
67-46	9554-9558	each	_	
67-47	9559-9562	ROI	_	
67-48	9562-9563	.	_	

#Text=In the analysis, p<0.05 was considered to be statistically significant.
68-1	9564-9566	In	_	
68-2	9567-9570	the	_	
68-3	9571-9579	analysis	_	
68-4	9579-9580	,	_	
68-5	9581-9582	p	_	
68-6	9582-9583	<	_	
68-7	9583-9587	0.05	_	
68-8	9588-9591	was	_	
68-9	9592-9602	considered	_	
68-10	9603-9605	to	_	
68-11	9606-9608	be	_	
68-12	9609-9622	statistically	_	
68-13	9623-9634	significant	_	
68-14	9634-9635	.	_	

#Text=Results
#Text=fMRI Results Based on ReHo
#Text=The brain regions with significant difference in ReHo are shown in Fig 1 and Table 2.
69-1	9636-9643	Results	_	
69-2	9644-9648	fMRI	_	
69-3	9649-9656	Results	_	
69-4	9657-9662	Based	_	
69-5	9663-9665	on	_	
69-6	9666-9670	ReHo	_	
69-7	9671-9674	The	_	
69-8	9675-9680	brain	_	
69-9	9681-9688	regions	_	
69-10	9689-9693	with	_	
69-11	9694-9705	significant	_	
69-12	9706-9716	difference	_	
69-13	9717-9719	in	_	
69-14	9720-9724	ReHo	_	
69-15	9725-9728	are	_	
69-16	9729-9734	shown	_	
69-17	9735-9737	in	_	
69-18	9738-9741	Fig	_	
69-19	9742-9743	1	_	
69-20	9744-9747	and	_	
69-21	9748-9753	Table	_	
69-22	9754-9755	2	_	
69-23	9755-9756	.	_	

#Text=Two ROIs showed a significantly decreased ReHo values in the smokers compared with those in the controls.
70-1	9757-9760	Two	_	
70-2	9761-9765	ROIs	_	
70-3	9766-9772	showed	_	
70-4	9773-9774	a	_	
70-5	9775-9788	significantly	_	
70-6	9789-9798	decreased	_	
70-7	9799-9803	ReHo	_	
70-8	9804-9810	values	_	
70-9	9811-9813	in	_	
70-10	9814-9817	the	_	
70-11	9818-9825	smokers	_	
70-12	9826-9834	compared	_	
70-13	9835-9839	with	_	
70-14	9840-9845	those	_	
70-15	9846-9848	in	_	
70-16	9849-9852	the	_	
70-17	9853-9861	controls	_	
70-18	9861-9862	.	_	

#Text=One ROI was located in the brain area of right superior frontal gyrus and right middle frontal gyrus in the Brodmann’s area (BA) 9.
71-1	9863-9866	One	_	
71-2	9867-9870	ROI	_	
71-3	9871-9874	was	_	
71-4	9875-9882	located	_	
71-5	9883-9885	in	_	
71-6	9886-9889	the	_	
71-7	9890-9895	brain	_	
71-8	9896-9900	area	_	
71-9	9901-9903	of	_	
71-10	9904-9909	right	_	
71-11	9910-9918	superior	_	
71-12	9919-9926	frontal	_	
71-13	9927-9932	gyrus	_	
71-14	9933-9936	and	_	
71-15	9937-9942	right	_	
71-16	9943-9949	middle	_	
71-17	9950-9957	frontal	_	
71-18	9958-9963	gyrus	_	
71-19	9964-9966	in	_	
71-20	9967-9970	the	_	
71-21	9971-9979	Brodmann	_	
71-22	9979-9980	’	_	
71-23	9980-9981	s	_	
71-24	9982-9986	area	_	
71-25	9987-9988	(	_	
71-26	9988-9990	BA	_	
71-27	9990-9991	)	_	
71-28	9992-9993	9	_	
71-29	9993-9994	.	_	

#Text=The other one was located in the left and right middle cingulum and the right precuneus in BA 23.
72-1	9995-9998	The	_	
72-2	9999-10004	other	_	
72-3	10005-10008	one	_	
72-4	10009-10012	was	_	
72-5	10013-10020	located	_	
72-6	10021-10023	in	_	
72-7	10024-10027	the	_	
72-8	10028-10032	left	_	
72-9	10033-10036	and	_	
72-10	10037-10042	right	_	
72-11	10043-10049	middle	_	
72-12	10050-10058	cingulum	_	
72-13	10059-10062	and	_	
72-14	10063-10066	the	_	
72-15	10067-10072	right	_	
72-16	10073-10082	precuneus	_	
72-17	10083-10085	in	_	
72-18	10086-10088	BA	_	
72-19	10089-10091	23	_	
72-20	10091-10092	.	_	

#Text=T-statistical difference maps between the smokers and the controls.
73-1	10093-10106	T-statistical	_	
73-2	10107-10117	difference	_	
73-3	10118-10122	maps	_	
73-4	10123-10130	between	_	
73-5	10131-10134	the	_	
73-6	10135-10142	smokers	_	
73-7	10143-10146	and	_	
73-8	10147-10150	the	_	
73-9	10151-10159	controls	_	
73-10	10159-10160	.	_	

#Text=Two-sample t-test, p<0.01, AlphaSim corrected.
74-1	10161-10171	Two-sample	_	
74-2	10172-10178	t-test	_	
74-3	10178-10179	,	_	
74-4	10180-10181	p	_	
74-5	10181-10182	<	_	
74-6	10182-10186	0.01	_	
74-7	10186-10187	,	_	
74-8	10188-10196	AlphaSim	_	
74-9	10197-10206	corrected	_	
74-10	10206-10207	.	_	

#Text=ROIs of significantly different ReHo values between smokers and controls.
75-1	10208-10212	ROIs	_	
75-2	10213-10215	of	_	
75-3	10216-10229	significantly	_	
75-4	10230-10239	different	_	
75-5	10240-10244	ReHo	_	
75-6	10245-10251	values	_	
75-7	10252-10259	between	_	
75-8	10260-10267	smokers	_	
75-9	10268-10271	and	_	
75-10	10272-10280	controls	_	
75-11	10280-10281	.	_	

#Text=Number of voxels\tBrain area\tBA\tPeak t value\tPeak coordinates (MNI)\t \tx\ty\tz\t \t1\t78\tsuperior frontal gyrus/R; middle frontal gyrus/R\t9\t−5.8927\t18\t48\t24\t \t2\t143\tprecuneus/L, R;middle cingulum gyrus/L, R\t23\t−6.2106\t−12\t−45\t39\t \t
#Text=R = right; L = left; BA = Brodmann’s area; MNI = Montreal Neurological Institute
#Text=Correlation Result Between ReHo and FTND
#Text=In each ROI, the voxel with the maximum t-value was selected for further analysis.
76-1	10283-10289	Number	_	
76-2	10290-10292	of	_	
76-3	10293-10299	voxels	_	
76-4	10300-10305	Brain	_	
76-5	10306-10310	area	_	
76-6	10311-10313	BA	_	
76-7	10314-10318	Peak	_	
76-8	10319-10320	t	_	
76-9	10321-10326	value	_	
76-10	10327-10331	Peak	_	
76-11	10332-10343	coordinates	_	
76-12	10344-10345	(	_	
76-13	10345-10348	MNI	_	
76-14	10348-10349	)	_	
76-15	10352-10353	x	_	
76-16	10354-10355	y	_	
76-17	10356-10357	z	_	
76-18	10360-10361	1	_	
76-19	10362-10364	78	_	
76-20	10365-10373	superior	_	
76-21	10374-10381	frontal	_	
76-22	10382-10387	gyrus	_	
76-23	10387-10388	/	_	
76-24	10388-10389	R	_	
76-25	10389-10390	;	_	
76-26	10391-10397	middle	_	
76-27	10398-10405	frontal	_	
76-28	10406-10411	gyrus	_	
76-29	10411-10412	/	_	
76-30	10412-10413	R	_	
76-31	10414-10415	9	_	
76-32	10416-10417	−	_	
76-33	10417-10423	5.8927	_	
76-34	10424-10426	18	_	
76-35	10427-10429	48	_	
76-36	10430-10432	24	_	
76-37	10435-10436	2	_	
76-38	10437-10440	143	_	
76-39	10441-10450	precuneus	_	
76-40	10450-10451	/	_	
76-41	10451-10452	L	_	
76-42	10452-10453	,	_	
76-43	10454-10455	R	_	
76-44	10455-10456	;	_	
76-45	10456-10462	middle	_	
76-46	10463-10471	cingulum	_	
76-47	10472-10477	gyrus	_	
76-48	10477-10478	/	_	
76-49	10478-10479	L	_	
76-50	10479-10480	,	_	
76-51	10481-10482	R	_	
76-52	10483-10485	23	_	
76-53	10486-10487	−	_	
76-54	10487-10493	6.2106	_	
76-55	10494-10495	−	_	
76-56	10495-10497	12	_	
76-57	10498-10499	−	_	
76-58	10499-10501	45	_	
76-59	10502-10504	39	_	
76-60	10508-10509	R	_	
76-61	10510-10511	=	_	
76-62	10512-10517	right	_	
76-63	10517-10518	;	_	
76-64	10519-10520	L	_	
76-65	10521-10522	=	_	
76-66	10523-10527	left	_	
76-67	10527-10528	;	_	
76-68	10529-10531	BA	_	
76-69	10532-10533	=	_	
76-70	10534-10542	Brodmann	_	
76-71	10542-10543	’	_	
76-72	10543-10544	s	_	
76-73	10545-10549	area	_	
76-74	10549-10550	;	_	
76-75	10551-10554	MNI	_	
76-76	10555-10556	=	_	
76-77	10557-10565	Montreal	_	
76-78	10566-10578	Neurological	_	
76-79	10579-10588	Institute	_	
76-80	10589-10600	Correlation	_	
76-81	10601-10607	Result	_	
76-82	10608-10615	Between	_	
76-83	10616-10620	ReHo	_	
76-84	10621-10624	and	_	
76-85	10625-10629	FTND	_	
76-86	10630-10632	In	_	
76-87	10633-10637	each	_	
76-88	10638-10641	ROI	_	
76-89	10641-10642	,	_	
76-90	10643-10646	the	_	
76-91	10647-10652	voxel	_	
76-92	10653-10657	with	_	
76-93	10658-10661	the	_	
76-94	10662-10669	maximum	_	
76-95	10670-10677	t-value	_	
76-96	10678-10681	was	_	
76-97	10682-10690	selected	_	
76-98	10691-10694	for	_	
76-99	10695-10702	further	_	
76-100	10703-10711	analysis	_	
76-101	10711-10712	.	_	

#Text=To examine the relationship between the clinical characteristics and the ReHo values in the ROI, correlation analysis was performed between FTND and mean ReHo in a sphere with 5 mm radius centered on the location with the peak voxel in each ROI.
77-1	10713-10715	To	_	
77-2	10716-10723	examine	_	
77-3	10724-10727	the	_	
77-4	10728-10740	relationship	_	
77-5	10741-10748	between	_	
77-6	10749-10752	the	_	
77-7	10753-10761	clinical	_	
77-8	10762-10777	characteristics	_	
77-9	10778-10781	and	_	
77-10	10782-10785	the	_	
77-11	10786-10790	ReHo	_	
77-12	10791-10797	values	_	
77-13	10798-10800	in	_	
77-14	10801-10804	the	_	
77-15	10805-10808	ROI	_	
77-16	10808-10809	,	_	
77-17	10810-10821	correlation	_	
77-18	10822-10830	analysis	_	
77-19	10831-10834	was	_	
77-20	10835-10844	performed	_	
77-21	10845-10852	between	_	
77-22	10853-10857	FTND	_	
77-23	10858-10861	and	_	
77-24	10862-10866	mean	_	
77-25	10867-10871	ReHo	_	
77-26	10872-10874	in	_	
77-27	10875-10876	a	_	
77-28	10877-10883	sphere	_	
77-29	10884-10888	with	_	
77-30	10889-10890	5	_	
77-31	10891-10893	mm	_	
77-32	10894-10900	radius	_	
77-33	10901-10909	centered	_	
77-34	10910-10912	on	_	
77-35	10913-10916	the	_	
77-36	10917-10925	location	_	
77-37	10926-10930	with	_	
77-38	10931-10934	the	_	
77-39	10935-10939	peak	_	
77-40	10940-10945	voxel	_	
77-41	10946-10948	in	_	
77-42	10949-10953	each	_	
77-43	10954-10957	ROI	_	
77-44	10957-10958	.	_	

#Text=As shown in Fig 2, the ReHo values were positively related to the FTND scores in the brain regions.
78-1	10959-10961	As	_	
78-2	10962-10967	shown	_	
78-3	10968-10970	in	_	
78-4	10971-10974	Fig	_	
78-5	10975-10976	2	_	
78-6	10976-10977	,	_	
78-7	10978-10981	the	_	
78-8	10982-10986	ReHo	_	
78-9	10987-10993	values	_	
78-10	10994-10998	were	_	
78-11	10999-11009	positively	_	
78-12	11010-11017	related	_	
78-13	11018-11020	to	_	
78-14	11021-11024	the	_	
78-15	11025-11029	FTND	_	
78-16	11030-11036	scores	_	
78-17	11037-11039	in	_	
78-18	11040-11043	the	_	
78-19	11044-11049	brain	_	
78-20	11050-11057	regions	_	
78-21	11057-11058	.	_	

#Text=Moreover, the ReHo value in the precuneus was significantly and positively correlated with the FTND score ((p<0.05, r = 0.5417); however, no correlation was observed in the superior frontal gyrus (p>0.05, r = 0.2934).
79-1	11059-11067	Moreover	_	
79-2	11067-11068	,	_	
79-3	11069-11072	the	_	
79-4	11073-11077	ReHo	_	
79-5	11078-11083	value	_	
79-6	11084-11086	in	_	
79-7	11087-11090	the	_	
79-8	11091-11100	precuneus	_	
79-9	11101-11104	was	_	
79-10	11105-11118	significantly	_	
79-11	11119-11122	and	_	
79-12	11123-11133	positively	_	
79-13	11134-11144	correlated	_	
79-14	11145-11149	with	_	
79-15	11150-11153	the	_	
79-16	11154-11158	FTND	_	
79-17	11159-11164	score	_	
79-18	11165-11166	(	_	
79-19	11166-11167	(	_	
79-20	11167-11168	p	_	
79-21	11168-11169	<	_	
79-22	11169-11173	0.05	_	
79-23	11173-11174	,	_	
79-24	11175-11176	r	_	
79-25	11177-11178	=	_	
79-26	11179-11185	0.5417	_	
79-27	11185-11186	)	_	
79-28	11186-11187	;	_	
79-29	11188-11195	however	_	
79-30	11195-11196	,	_	
79-31	11197-11199	no	_	
79-32	11200-11211	correlation	_	
79-33	11212-11215	was	_	
79-34	11216-11224	observed	_	
79-35	11225-11227	in	_	
79-36	11228-11231	the	_	
79-37	11232-11240	superior	_	
79-38	11241-11248	frontal	_	
79-39	11249-11254	gyrus	_	
79-40	11255-11256	(	_	
79-41	11256-11257	p	_	
79-42	11257-11258	>	_	
79-43	11258-11262	0.05	_	
79-44	11262-11263	,	_	
79-45	11264-11265	r	_	
79-46	11266-11267	=	_	
79-47	11268-11274	0.2934	_	
79-48	11274-11275	)	_	
79-49	11275-11276	.	_	

#Text=Results of correlation analysis between the FTND score and the ReHo value in smokers.
80-1	11277-11284	Results	_	
80-2	11285-11287	of	_	
80-3	11288-11299	correlation	_	
80-4	11300-11308	analysis	_	
80-5	11309-11316	between	_	
80-6	11317-11320	the	_	
80-7	11321-11325	FTND	_	
80-8	11326-11331	score	_	
80-9	11332-11335	and	_	
80-10	11336-11339	the	_	
80-11	11340-11344	ReHo	_	
80-12	11345-11350	value	_	
80-13	11351-11353	in	_	
80-14	11354-11361	smokers	_	
80-15	11361-11362	.	_	

#Text=A.
81-1	11363-11364	A	_	
81-2	11364-11365	.	_	

#Text=The ReHo value in the superior frontal gyrus is insignificant and positively correlated with the FTND of the smokers (p>0.05, r = 0.2934); B.
82-1	11366-11369	The	_	
82-2	11370-11374	ReHo	_	
82-3	11375-11380	value	_	
82-4	11381-11383	in	_	
82-5	11384-11387	the	_	
82-6	11388-11396	superior	_	
82-7	11397-11404	frontal	_	
82-8	11405-11410	gyrus	_	
82-9	11411-11413	is	_	
82-10	11414-11427	insignificant	_	
82-11	11428-11431	and	_	
82-12	11432-11442	positively	_	
82-13	11443-11453	correlated	_	
82-14	11454-11458	with	_	
82-15	11459-11462	the	_	
82-16	11463-11467	FTND	_	
82-17	11468-11470	of	_	
82-18	11471-11474	the	_	
82-19	11475-11482	smokers	_	
82-20	11483-11484	(	_	
82-21	11484-11485	p	_	
82-22	11485-11486	>	_	
82-23	11486-11490	0.05	_	
82-24	11490-11491	,	_	
82-25	11492-11493	r	_	
82-26	11494-11495	=	_	
82-27	11496-11502	0.2934	_	
82-28	11502-11503	)	_	
82-29	11503-11504	;	_	
82-30	11505-11506	B	_	
82-31	11506-11507	.	_	

#Text=The ReHo value in the precuneus is significant and positively correlated with the FTND score of the smokers (p<0.05, r = 0.5417).
83-1	11508-11511	The	_	
83-2	11512-11516	ReHo	_	
83-3	11517-11522	value	_	
83-4	11523-11525	in	_	
83-5	11526-11529	the	_	
83-6	11530-11539	precuneus	_	
83-7	11540-11542	is	_	
83-8	11543-11554	significant	_	
83-9	11555-11558	and	_	
83-10	11559-11569	positively	_	
83-11	11570-11580	correlated	_	
83-12	11581-11585	with	_	
83-13	11586-11589	the	_	
83-14	11590-11594	FTND	_	
83-15	11595-11600	score	_	
83-16	11601-11603	of	_	
83-17	11604-11607	the	_	
83-18	11608-11615	smokers	_	
83-19	11616-11617	(	_	
83-20	11617-11618	p	_	
83-21	11618-11619	<	_	
83-22	11619-11623	0.05	_	
83-23	11623-11624	,	_	
83-24	11625-11626	r	_	
83-25	11627-11628	=	_	
83-26	11629-11635	0.5417	_	
83-27	11635-11636	)	_	
83-28	11636-11637	.	_	

#Text=FTND = Fagerstrom Test for Nicotine Dependence.
84-1	11638-11642	FTND	_	
84-2	11643-11644	=	_	
84-3	11645-11655	Fagerstrom	_	
84-4	11656-11660	Test	_	
84-5	11661-11664	for	_	
84-6	11665-11673	Nicotine	_	
84-7	11674-11684	Dependence	_	
84-8	11684-11685	.	_	

#Text=Discussion
#Text=In the present study, we conducted an rs-fMRI experiment to investigate the difference between smokers and non-smokers.
85-1	11686-11696	Discussion	_	
85-2	11697-11699	In	_	
85-3	11700-11703	the	_	
85-4	11704-11711	present	_	
85-5	11712-11717	study	_	
85-6	11717-11718	,	_	
85-7	11719-11721	we	_	
85-8	11722-11731	conducted	_	
85-9	11732-11734	an	_	
85-10	11735-11742	rs-fMRI	_	
85-11	11743-11753	experiment	_	
85-12	11754-11756	to	_	
85-13	11757-11768	investigate	_	
85-14	11769-11772	the	_	
85-15	11773-11783	difference	_	
85-16	11784-11791	between	_	
85-17	11792-11799	smokers	_	
85-18	11800-11803	and	_	
85-19	11804-11815	non-smokers	_	
85-20	11815-11816	.	_	

#Text=In the experiment, 14 smokers and 11 non-smokers were scanned.
86-1	11817-11819	In	_	
86-2	11820-11823	the	_	
86-3	11824-11834	experiment	_	
86-4	11834-11835	,	_	
86-5	11836-11838	14	_	
86-6	11839-11846	smokers	_	
86-7	11847-11850	and	_	
86-8	11851-11853	11	_	
86-9	11854-11865	non-smokers	_	
86-10	11866-11870	were	_	
86-11	11871-11878	scanned	_	
86-12	11878-11879	.	_	

#Text=The experimental results show that the ReHo value from the right superior frontal gyrus (BA 9) to the right middle frontal gyrus and that from the precuneus (BA 23) to the middle cingulum gyrus were lower in the smokers than in the non-smokers.
87-1	11880-11883	The	_	
87-2	11884-11896	experimental	_	
87-3	11897-11904	results	_	
87-4	11905-11909	show	_	
87-5	11910-11914	that	_	
87-6	11915-11918	the	_	
87-7	11919-11923	ReHo	_	
87-8	11924-11929	value	_	
87-9	11930-11934	from	_	
87-10	11935-11938	the	_	
87-11	11939-11944	right	_	
87-12	11945-11953	superior	_	
87-13	11954-11961	frontal	_	
87-14	11962-11967	gyrus	_	
87-15	11968-11969	(	_	
87-16	11969-11971	BA	_	
87-17	11972-11973	9	_	
87-18	11973-11974	)	_	
87-19	11975-11977	to	_	
87-20	11978-11981	the	_	
87-21	11982-11987	right	_	
87-22	11988-11994	middle	_	
87-23	11995-12002	frontal	_	
87-24	12003-12008	gyrus	_	
87-25	12009-12012	and	_	
87-26	12013-12017	that	_	
87-27	12018-12022	from	_	
87-28	12023-12026	the	_	
87-29	12027-12036	precuneus	_	
87-30	12037-12038	(	_	
87-31	12038-12040	BA	_	
87-32	12041-12043	23	_	
87-33	12043-12044	)	_	
87-34	12045-12047	to	_	
87-35	12048-12051	the	_	
87-36	12052-12058	middle	_	
87-37	12059-12067	cingulum	_	
87-38	12068-12073	gyrus	_	
87-39	12074-12078	were	_	
87-40	12079-12084	lower	_	
87-41	12085-12087	in	_	
87-42	12088-12091	the	_	
87-43	12092-12099	smokers	_	
87-44	12100-12104	than	_	
87-45	12105-12107	in	_	
87-46	12108-12111	the	_	
87-47	12112-12123	non-smokers	_	
87-48	12123-12124	.	_	

#Text=The ReHo value in the precuneus (BA 23) was significant and positively correlated with the FTND score of smokers.
88-1	12125-12128	The	_	
88-2	12129-12133	ReHo	_	
88-3	12134-12139	value	_	
88-4	12140-12142	in	_	
88-5	12143-12146	the	_	
88-6	12147-12156	precuneus	_	
88-7	12157-12158	(	_	
88-8	12158-12160	BA	_	
88-9	12161-12163	23	_	
88-10	12163-12164	)	_	
88-11	12165-12168	was	_	
88-12	12169-12180	significant	_	
88-13	12181-12184	and	_	
88-14	12185-12195	positively	_	
88-15	12196-12206	correlated	_	
88-16	12207-12211	with	_	
88-17	12212-12215	the	_	
88-18	12216-12220	FTND	_	
88-19	12221-12226	score	_	
88-20	12227-12229	of	_	
88-21	12230-12237	smokers	_	
88-22	12237-12238	.	_	

#Text=These findings verify our hypothesis that the ReHo value of resting-state brain activity would be different between the smokers and the controls.
89-1	12239-12244	These	_	
89-2	12245-12253	findings	_	
89-3	12254-12260	verify	_	
89-4	12261-12264	our	_	
89-5	12265-12275	hypothesis	_	
89-6	12276-12280	that	_	
89-7	12281-12284	the	_	
89-8	12285-12289	ReHo	_	
89-9	12290-12295	value	_	
89-10	12296-12298	of	_	
89-11	12299-12312	resting-state	_	
89-12	12313-12318	brain	_	
89-13	12319-12327	activity	_	
89-14	12328-12333	would	_	
89-15	12334-12336	be	_	
89-16	12337-12346	different	_	
89-17	12347-12354	between	_	
89-18	12355-12358	the	_	
89-19	12359-12366	smokers	_	
89-20	12367-12370	and	_	
89-21	12371-12374	the	_	
89-22	12375-12383	controls	_	
89-23	12383-12384	.	_	

#Text=The rs-fMRI technology is concerned with the neuronal activity in the absence of a task and has been used to indirectly measure neuronal activity.
90-1	12385-12388	The	_	
90-2	12389-12396	rs-fMRI	_	
90-3	12397-12407	technology	_	
90-4	12408-12410	is	_	
90-5	12411-12420	concerned	_	
90-6	12421-12425	with	_	
90-7	12426-12429	the	_	
90-8	12430-12438	neuronal	_	
90-9	12439-12447	activity	_	
90-10	12448-12450	in	_	
90-11	12451-12454	the	_	
90-12	12455-12462	absence	_	
90-13	12463-12465	of	_	
90-14	12466-12467	a	_	
90-15	12468-12472	task	_	
90-16	12473-12476	and	_	
90-17	12477-12480	has	_	
90-18	12481-12485	been	_	
90-19	12486-12490	used	_	
90-20	12491-12493	to	_	
90-21	12494-12504	indirectly	_	
90-22	12505-12512	measure	_	
90-23	12513-12521	neuronal	_	
90-24	12522-12530	activity	_	
90-25	12530-12531	.	_	

#Text=As a principal method for rs-fMRI, ReHo is emerging as an interesting biomarker for measuring the means of diseases.
91-1	12532-12534	As	_	
91-2	12535-12536	a	_	
91-3	12537-12546	principal	_	
91-4	12547-12553	method	_	
91-5	12554-12557	for	_	
91-6	12558-12565	rs-fMRI	_	
91-7	12565-12566	,	_	
91-8	12567-12571	ReHo	_	
91-9	12572-12574	is	_	
91-10	12575-12583	emerging	_	
91-11	12584-12586	as	_	
91-12	12587-12589	an	_	
91-13	12590-12601	interesting	_	
91-14	12602-12611	biomarker	_	
91-15	12612-12615	for	_	
91-16	12616-12625	measuring	_	
91-17	12626-12629	the	_	
91-18	12630-12635	means	_	
91-19	12636-12638	of	_	
91-20	12639-12647	diseases	_	
91-21	12647-12648	.	_	

#Text=The ReHo values in the right medial prefrontal-caudate circuit may represent an important biomarker of violence in juvenile males.
92-1	12649-12652	The	_	
92-2	12653-12657	ReHo	_	
92-3	12658-12664	values	_	
92-4	12665-12667	in	_	
92-5	12668-12671	the	_	
92-6	12672-12677	right	_	
92-7	12678-12684	medial	_	
92-8	12685-12703	prefrontal-caudate	_	
92-9	12704-12711	circuit	_	
92-10	12712-12715	may	_	
92-11	12716-12725	represent	_	
92-12	12726-12728	an	_	
92-13	12729-12738	important	_	
92-14	12739-12748	biomarker	_	
92-15	12749-12751	of	_	
92-16	12752-12760	violence	_	
92-17	12761-12763	in	_	
92-18	12764-12772	juvenile	_	
92-19	12773-12778	males	_	
92-20	12778-12779	.	_	

#Text=The ReHo abnormalities are a potential biomarker for the diagnosis of Parkinson’s disease, and they provide insights into the biological mechanism of the disease.
93-1	12780-12783	The	_	
93-2	12784-12788	ReHo	_	
93-3	12789-12802	abnormalities	_	
93-4	12803-12806	are	_	
93-5	12807-12808	a	_	
93-6	12809-12818	potential	_	
93-7	12819-12828	biomarker	_	
93-8	12829-12832	for	_	
93-9	12833-12836	the	_	
93-10	12837-12846	diagnosis	_	
93-11	12847-12849	of	_	
93-12	12850-12859	Parkinson	_	
93-13	12859-12860	’	_	
93-14	12860-12861	s	_	
93-15	12862-12869	disease	_	
93-16	12869-12870	,	_	
93-17	12871-12874	and	_	
93-18	12875-12879	they	_	
93-19	12880-12887	provide	_	
93-20	12888-12896	insights	_	
93-21	12897-12901	into	_	
93-22	12902-12905	the	_	
93-23	12906-12916	biological	_	
93-24	12917-12926	mechanism	_	
93-25	12927-12929	of	_	
93-26	12930-12933	the	_	
93-27	12934-12941	disease	_	
93-28	12941-12942	.	_	

#Text=Zhan et al. experimentally demonstrated that ReHo may provide an objective biomarker for evaluating the functional abnormity of mild traumatic brain injury under acute settings.
94-1	12943-12947	Zhan	_	
94-2	12948-12950	et	_	
94-3	12951-12953	al	_	
94-4	12953-12954	.	_	
94-5	12955-12969	experimentally	_	
94-6	12970-12982	demonstrated	_	
94-7	12983-12987	that	_	
94-8	12988-12992	ReHo	_	
94-9	12993-12996	may	_	
94-10	12997-13004	provide	_	
94-11	13005-13007	an	_	
94-12	13008-13017	objective	_	
94-13	13018-13027	biomarker	_	
94-14	13028-13031	for	_	
94-15	13032-13042	evaluating	_	
94-16	13043-13046	the	_	
94-17	13047-13057	functional	_	
94-18	13058-13067	abnormity	_	
94-19	13068-13070	of	_	
94-20	13071-13075	mild	_	
94-21	13076-13085	traumatic	_	
94-22	13086-13091	brain	_	
94-23	13092-13098	injury	_	
94-24	13099-13104	under	_	
94-25	13105-13110	acute	_	
94-26	13111-13119	settings	_	
94-27	13119-13120	.	_	

#Text=Liu et al. proposed that ReHo is a potential neuroimaging biomarker for distinguishing bipolar disorder patients experiencing a depressive episode and unipolar depression patients.
95-1	13121-13124	Liu	_	
95-2	13125-13127	et	_	
95-3	13128-13130	al	_	
95-4	13130-13131	.	_	
95-5	13132-13140	proposed	_	
95-6	13141-13145	that	_	
95-7	13146-13150	ReHo	_	
95-8	13151-13153	is	_	
95-9	13154-13155	a	_	
95-10	13156-13165	potential	_	
95-11	13166-13178	neuroimaging	_	
95-12	13179-13188	biomarker	_	
95-13	13189-13192	for	_	
95-14	13193-13207	distinguishing	_	
95-15	13208-13215	bipolar	_	
95-16	13216-13224	disorder	_	
95-17	13225-13233	patients	_	
95-18	13234-13246	experiencing	_	
95-19	13247-13248	a	_	
95-20	13249-13259	depressive	_	
95-21	13260-13267	episode	_	
95-22	13268-13271	and	_	
95-23	13272-13280	unipolar	_	
95-24	13281-13291	depression	_	
95-25	13292-13300	patients	_	
95-26	13300-13301	.	_	

#Text=Yuan et al. indicated that amnestic mild cognitive impairment patients show significant abnormal local coherence of biological activity in resting state, and ReHo can serve as a sensitive biomarker in functional imaging studies.
96-1	13302-13306	Yuan	_	
96-2	13307-13309	et	_	
96-3	13310-13312	al	_	
96-4	13312-13313	.	_	
96-5	13314-13323	indicated	_	
96-6	13324-13328	that	_	
96-7	13329-13337	amnestic	_	
96-8	13338-13342	mild	_	
96-9	13343-13352	cognitive	_	
96-10	13353-13363	impairment	_	
96-11	13364-13372	patients	_	
96-12	13373-13377	show	_	
96-13	13378-13389	significant	_	
96-14	13390-13398	abnormal	_	
96-15	13399-13404	local	_	
96-16	13405-13414	coherence	_	
96-17	13415-13417	of	_	
96-18	13418-13428	biological	_	
96-19	13429-13437	activity	_	
96-20	13438-13440	in	_	
96-21	13441-13448	resting	_	
96-22	13449-13454	state	_	
96-23	13454-13455	,	_	
96-24	13456-13459	and	_	
96-25	13460-13464	ReHo	_	
96-26	13465-13468	can	_	
96-27	13469-13474	serve	_	
96-28	13475-13477	as	_	
96-29	13478-13479	a	_	
96-30	13480-13489	sensitive	_	
96-31	13490-13499	biomarker	_	
96-32	13500-13502	in	_	
96-33	13503-13513	functional	_	
96-34	13514-13521	imaging	_	
96-35	13522-13529	studies	_	
96-36	13529-13530	.	_	

#Text=In addition, Chen et al. suggested that ReHo can be helpful in detecting minimal hepatic encephalopathy in cirrhotic patients.
97-1	13531-13533	In	_	
97-2	13534-13542	addition	_	
97-3	13542-13543	,	_	
97-4	13544-13548	Chen	_	
97-5	13549-13551	et	_	
97-6	13552-13554	al	_	
97-7	13554-13555	.	_	
97-8	13556-13565	suggested	_	
97-9	13566-13570	that	_	
97-10	13571-13575	ReHo	_	
97-11	13576-13579	can	_	
97-12	13580-13582	be	_	
97-13	13583-13590	helpful	_	
97-14	13591-13593	in	_	
97-15	13594-13603	detecting	_	
97-16	13604-13611	minimal	_	
97-17	13612-13619	hepatic	_	
97-18	13620-13634	encephalopathy	_	
97-19	13635-13637	in	_	
97-20	13638-13647	cirrhotic	_	
97-21	13648-13656	patients	_	
97-22	13656-13657	.	_	

#Text=The results of current study suggest that the ReHo values in the right superior frontal gyrus and left precuneus can be used to separate the smokers from the non-smokers.
98-1	13658-13661	The	_	
98-2	13662-13669	results	_	
98-3	13670-13672	of	_	
98-4	13673-13680	current	_	
98-5	13681-13686	study	_	
98-6	13687-13694	suggest	_	
98-7	13695-13699	that	_	
98-8	13700-13703	the	_	
98-9	13704-13708	ReHo	_	
98-10	13709-13715	values	_	
98-11	13716-13718	in	_	
98-12	13719-13722	the	_	
98-13	13723-13728	right	_	
98-14	13729-13737	superior	_	
98-15	13738-13745	frontal	_	
98-16	13746-13751	gyrus	_	
98-17	13752-13755	and	_	
98-18	13756-13760	left	_	
98-19	13761-13770	precuneus	_	
98-20	13771-13774	can	_	
98-21	13775-13777	be	_	
98-22	13778-13782	used	_	
98-23	13783-13785	to	_	
98-24	13786-13794	separate	_	
98-25	13795-13798	the	_	
98-26	13799-13806	smokers	_	
98-27	13807-13811	from	_	
98-28	13812-13815	the	_	
98-29	13816-13827	non-smokers	_	
98-30	13827-13828	.	_	

#Text=In particular, the left precuneus with the ReHo value that significantly correlates with the FTND score of smokers can be a potential neuroimaging biomarker for nicotine addicts.
99-1	13829-13831	In	_	
99-2	13832-13842	particular	_	
99-3	13842-13843	,	_	
99-4	13844-13847	the	_	
99-5	13848-13852	left	_	
99-6	13853-13862	precuneus	_	
99-7	13863-13867	with	_	
99-8	13868-13871	the	_	
99-9	13872-13876	ReHo	_	
99-10	13877-13882	value	_	
99-11	13883-13887	that	_	
99-12	13888-13901	significantly	_	
99-13	13902-13912	correlates	_	
99-14	13913-13917	with	_	
99-15	13918-13921	the	_	
99-16	13922-13926	FTND	_	
99-17	13927-13932	score	_	
99-18	13933-13935	of	_	
99-19	13936-13943	smokers	_	
99-20	13944-13947	can	_	
99-21	13948-13950	be	_	
99-22	13951-13952	a	_	
99-23	13953-13962	potential	_	
99-24	13963-13975	neuroimaging	_	
99-25	13976-13985	biomarker	_	
99-26	13986-13989	for	_	
99-27	13990-13998	nicotine	_	
99-28	13999-14006	addicts	_	
99-29	14006-14007	.	_	

#Text=The function for the brain areas of superior frontal gyrus and precuneus was related to the working memory in previous studies.
100-1	14008-14011	The	_	
100-2	14012-14020	function	_	
100-3	14021-14024	for	_	
100-4	14025-14028	the	_	
100-5	14029-14034	brain	_	
100-6	14035-14040	areas	_	
100-7	14041-14043	of	_	
100-8	14044-14052	superior	_	
100-9	14053-14060	frontal	_	
100-10	14061-14066	gyrus	_	
100-11	14067-14070	and	_	
100-12	14071-14080	precuneus	_	
100-13	14081-14084	was	_	
100-14	14085-14092	related	_	
100-15	14093-14095	to	_	
100-16	14096-14099	the	_	
100-17	14100-14107	working	_	
100-18	14108-14114	memory	_	
100-19	14115-14117	in	_	
100-20	14118-14126	previous	_	
100-21	14127-14134	studies	_	
100-22	14134-14135	.	_	

#Text=A structural network research had shown that the precuneus, middle frontal gyrus, and superior frontal gyrus exhibit significantly high connectivity indices, which are remarkably related to variations in working memory capacity.
101-1	14136-14137	A	_	
101-2	14138-14148	structural	_	
101-3	14149-14156	network	_	
101-4	14157-14165	research	_	
101-5	14166-14169	had	_	
101-6	14170-14175	shown	_	
101-7	14176-14180	that	_	
101-8	14181-14184	the	_	
101-9	14185-14194	precuneus	_	
101-10	14194-14195	,	_	
101-11	14196-14202	middle	_	
101-12	14203-14210	frontal	_	
101-13	14211-14216	gyrus	_	
101-14	14216-14217	,	_	
101-15	14218-14221	and	_	
101-16	14222-14230	superior	_	
101-17	14231-14238	frontal	_	
101-18	14239-14244	gyrus	_	
101-19	14245-14252	exhibit	_	
101-20	14253-14266	significantly	_	
101-21	14267-14271	high	_	
101-22	14272-14284	connectivity	_	
101-23	14285-14292	indices	_	
101-24	14292-14293	,	_	
101-25	14294-14299	which	_	
101-26	14300-14303	are	_	
101-27	14304-14314	remarkably	_	
101-28	14315-14322	related	_	
101-29	14323-14325	to	_	
101-30	14326-14336	variations	_	
101-31	14337-14339	in	_	
101-32	14340-14347	working	_	
101-33	14348-14354	memory	_	
101-34	14355-14363	capacity	_	
101-35	14363-14364	.	_	

#Text=The repetitive transcranial magnetic stimulation has been navigated on the precuneus region, thereby resulting in a robust bilateral field advantage in visual short-term memory storage capacity.
102-1	14365-14368	The	_	
102-2	14369-14379	repetitive	_	
102-3	14380-14392	transcranial	_	
102-4	14393-14401	magnetic	_	
102-5	14402-14413	stimulation	_	
102-6	14414-14417	has	_	
102-7	14418-14422	been	_	
102-8	14423-14432	navigated	_	
102-9	14433-14435	on	_	
102-10	14436-14439	the	_	
102-11	14440-14449	precuneus	_	
102-12	14450-14456	region	_	
102-13	14456-14457	,	_	
102-14	14458-14465	thereby	_	
102-15	14466-14475	resulting	_	
102-16	14476-14478	in	_	
102-17	14479-14480	a	_	
102-18	14481-14487	robust	_	
102-19	14488-14497	bilateral	_	
102-20	14498-14503	field	_	
102-21	14504-14513	advantage	_	
102-22	14514-14516	in	_	
102-23	14517-14523	visual	_	
102-24	14524-14534	short-term	_	
102-25	14535-14541	memory	_	
102-26	14542-14549	storage	_	
102-27	14550-14558	capacity	_	
102-28	14558-14559	.	_	

#Text=Systemic lupus erythematosus patients with memory impairment show significant hypoperfusion in the right precuneus compared with those with non-memory impairment; therefore, hypoperfusion of the precuneus may play a significant role in the memory function of systemic lupus erythematosus patients.
103-1	14560-14568	Systemic	_	
103-2	14569-14574	lupus	_	
103-3	14575-14588	erythematosus	_	
103-4	14589-14597	patients	_	
103-5	14598-14602	with	_	
103-6	14603-14609	memory	_	
103-7	14610-14620	impairment	_	
103-8	14621-14625	show	_	
103-9	14626-14637	significant	_	
103-10	14638-14651	hypoperfusion	_	
103-11	14652-14654	in	_	
103-12	14655-14658	the	_	
103-13	14659-14664	right	_	
103-14	14665-14674	precuneus	_	
103-15	14675-14683	compared	_	
103-16	14684-14688	with	_	
103-17	14689-14694	those	_	
103-18	14695-14699	with	_	
103-19	14700-14710	non-memory	_	
103-20	14711-14721	impairment	_	
103-21	14721-14722	;	_	
103-22	14723-14732	therefore	_	
103-23	14732-14733	,	_	
103-24	14734-14747	hypoperfusion	_	
103-25	14748-14750	of	_	
103-26	14751-14754	the	_	
103-27	14755-14764	precuneus	_	
103-28	14765-14768	may	_	
103-29	14769-14773	play	_	
103-30	14774-14775	a	_	
103-31	14776-14787	significant	_	
103-32	14788-14792	role	_	
103-33	14793-14795	in	_	
103-34	14796-14799	the	_	
103-35	14800-14806	memory	_	
103-36	14807-14815	function	_	
103-37	14816-14818	of	_	
103-38	14819-14827	systemic	_	
103-39	14828-14833	lupus	_	
103-40	14834-14847	erythematosus	_	
103-41	14848-14856	patients	_	
103-42	14856-14857	.	_	

#Text=The results of the present study imply that the smokers are significantly different from the non-smokers in terms of working memory.
104-1	14858-14861	The	_	
104-2	14862-14869	results	_	
104-3	14870-14872	of	_	
104-4	14873-14876	the	_	
104-5	14877-14884	present	_	
104-6	14885-14890	study	_	
104-7	14891-14896	imply	_	
104-8	14897-14901	that	_	
104-9	14902-14905	the	_	
104-10	14906-14913	smokers	_	
104-11	14914-14917	are	_	
104-12	14918-14931	significantly	_	
104-13	14932-14941	different	_	
104-14	14942-14946	from	_	
104-15	14947-14950	the	_	
104-16	14951-14962	non-smokers	_	
104-17	14963-14965	in	_	
104-18	14966-14971	terms	_	
104-19	14972-14974	of	_	
104-20	14975-14982	working	_	
104-21	14983-14989	memory	_	
104-22	14989-14990	.	_	

#Text=Studying the particular cognitive function of nicotine addicts is thus important.
105-1	14991-14999	Studying	_	
105-2	15000-15003	the	_	
105-3	15004-15014	particular	_	
105-4	15015-15024	cognitive	_	
105-5	15025-15033	function	_	
105-6	15034-15036	of	_	
105-7	15037-15045	nicotine	_	
105-8	15046-15053	addicts	_	
105-9	15054-15056	is	_	
105-10	15057-15061	thus	_	
105-11	15062-15071	important	_	
105-12	15071-15072	.	_	

#Text=The current study has several limitations.
106-1	15073-15076	The	_	
106-2	15077-15084	current	_	
106-3	15085-15090	study	_	
106-4	15091-15094	has	_	
106-5	15095-15102	several	_	
106-6	15103-15114	limitations	_	
106-7	15114-15115	.	_	

#Text=First, our results are limited to a small sample size, which may affect the statistical analysis and comprehensive interpretation of the findings.
107-1	15116-15121	First	_	
107-2	15121-15122	,	_	
107-3	15123-15126	our	_	
107-4	15127-15134	results	_	
107-5	15135-15138	are	_	
107-6	15139-15146	limited	_	
107-7	15147-15149	to	_	
107-8	15150-15151	a	_	
107-9	15152-15157	small	_	
107-10	15158-15164	sample	_	
107-11	15165-15169	size	_	
107-12	15169-15170	,	_	
107-13	15171-15176	which	_	
107-14	15177-15180	may	_	
107-15	15181-15187	affect	_	
107-16	15188-15191	the	_	
107-17	15192-15203	statistical	_	
107-18	15204-15212	analysis	_	
107-19	15213-15216	and	_	
107-20	15217-15230	comprehensive	_	
107-21	15231-15245	interpretation	_	
107-22	15246-15248	of	_	
107-23	15249-15252	the	_	
107-24	15253-15261	findings	_	
107-25	15261-15262	.	_	

#Text=Further studies with high number of patients of homogeneous etiology are needed, as well as high number of nicotine addicts.
108-1	15263-15270	Further	_	
108-2	15271-15278	studies	_	
108-3	15279-15283	with	_	
108-4	15284-15288	high	_	
108-5	15289-15295	number	_	
108-6	15296-15298	of	_	
108-7	15299-15307	patients	_	
108-8	15308-15310	of	_	
108-9	15311-15322	homogeneous	_	
108-10	15323-15331	etiology	_	
108-11	15332-15335	are	_	
108-12	15336-15342	needed	_	
108-13	15342-15343	,	_	
108-14	15344-15346	as	_	
108-15	15347-15351	well	_	
108-16	15352-15354	as	_	
108-17	15355-15359	high	_	
108-18	15360-15366	number	_	
108-19	15367-15369	of	_	
108-20	15370-15378	nicotine	_	
108-21	15379-15386	addicts	_	
108-22	15386-15387	.	_	

#Text=Second, the origin of ReHo and the neurophysiological basis remain unclear.
109-1	15388-15394	Second	_	
109-2	15394-15395	,	_	
109-3	15396-15399	the	_	
109-4	15400-15406	origin	_	
109-5	15407-15409	of	_	
109-6	15410-15414	ReHo	_	
109-7	15415-15418	and	_	
109-8	15419-15422	the	_	
109-9	15423-15441	neurophysiological	_	
109-10	15442-15447	basis	_	
109-11	15448-15454	remain	_	
109-12	15455-15462	unclear	_	
109-13	15462-15463	.	_	

#Text=These aspects must be further studied in the future.
110-1	15464-15469	These	_	
110-2	15470-15477	aspects	_	
110-3	15478-15482	must	_	
110-4	15483-15485	be	_	
110-5	15486-15493	further	_	
110-6	15494-15501	studied	_	
110-7	15502-15504	in	_	
110-8	15505-15508	the	_	
110-9	15509-15515	future	_	
110-10	15515-15516	.	_	

#Text=In summary, we used ReHo based on rs-fMRI to explore the objective biomarker for nicotine dependence evaluation.
111-1	15517-15519	In	_	
111-2	15520-15527	summary	_	
111-3	15527-15528	,	_	
111-4	15529-15531	we	_	
111-5	15532-15536	used	_	
111-6	15537-15541	ReHo	_	
111-7	15542-15547	based	_	
111-8	15548-15550	on	_	
111-9	15551-15558	rs-fMRI	_	
111-10	15559-15561	to	_	
111-11	15562-15569	explore	_	
111-12	15570-15573	the	_	
111-13	15574-15583	objective	_	
111-14	15584-15593	biomarker	_	
111-15	15594-15597	for	_	
111-16	15598-15606	nicotine	_	
111-17	15607-15617	dependence	_	
111-18	15618-15628	evaluation	_	
111-19	15628-15629	.	_	

#Text=The results show that the ReHo values in the right superior frontal gyrus and left precuneus can be used to separate the smokers from the non-smokers.
112-1	15630-15633	The	_	
112-2	15634-15641	results	_	
112-3	15642-15646	show	_	
112-4	15647-15651	that	_	
112-5	15652-15655	the	_	
112-6	15656-15660	ReHo	_	
112-7	15661-15667	values	_	
112-8	15668-15670	in	_	
112-9	15671-15674	the	_	
112-10	15675-15680	right	_	
112-11	15681-15689	superior	_	
112-12	15690-15697	frontal	_	
112-13	15698-15703	gyrus	_	
112-14	15704-15707	and	_	
112-15	15708-15712	left	_	
112-16	15713-15722	precuneus	_	
112-17	15723-15726	can	_	
112-18	15727-15729	be	_	
112-19	15730-15734	used	_	
112-20	15735-15737	to	_	
112-21	15738-15746	separate	_	
112-22	15747-15750	the	_	
112-23	15751-15758	smokers	_	
112-24	15759-15763	from	_	
112-25	15764-15767	the	_	
112-26	15768-15779	non-smokers	_	
112-27	15779-15780	.	_	

#Text=Moreover, the ReHo value in the left precuneus is significantly correlated with the FTND score of smokers.
113-1	15781-15789	Moreover	_	
113-2	15789-15790	,	_	
113-3	15791-15794	the	_	
113-4	15795-15799	ReHo	_	
113-5	15800-15805	value	_	
113-6	15806-15808	in	_	
113-7	15809-15812	the	_	
113-8	15813-15817	left	_	
113-9	15818-15827	precuneus	_	
113-10	15828-15830	is	_	
113-11	15831-15844	significantly	_	
113-12	15845-15855	correlated	_	
113-13	15856-15860	with	_	
113-14	15861-15864	the	_	
113-15	15865-15869	FTND	_	
113-16	15870-15875	score	_	
113-17	15876-15878	of	_	
113-18	15879-15886	smokers	_	
113-19	15886-15887	.	_	

#Text=These findings suggest that left precuneus is a potential neuroimaging biomarker for nicotine addicts.
114-1	15888-15893	These	_	
114-2	15894-15902	findings	_	
114-3	15903-15910	suggest	_	
114-4	15911-15915	that	_	
114-5	15916-15920	left	_	
114-6	15921-15930	precuneus	_	
114-7	15931-15933	is	_	
114-8	15934-15935	a	_	
114-9	15936-15945	potential	_	
114-10	15946-15958	neuroimaging	_	
114-11	15959-15968	biomarker	_	
114-12	15969-15972	for	_	
114-13	15973-15981	nicotine	_	
114-14	15982-15989	addicts	_	
114-15	15989-15990	.	_	

#Text=References
#Text=The Health Consequences of Smoking: A Report of the Surgeon General
#Text=elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype
#Text=Cigarette smoking leads to persistent and dose-dependent alterations of brain activity and connectivity in anterior insula and anterior cingulate
#Text=Neural sensitivity to smoking stimuli is associated with cigarette craving in adolescent smokers
#Text=Chronic cigarette smoking is linked with structural alterations in brain regions showing acute nicotinic drug-induced functional modulations
#Text=The effects of nicotine and non-nicotine smoking factors on working memory and associated brain function
#Text=Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging
#Text=Functional and effective connectivity: a review
#Text=Increased frontal functional networks in adult survivors of childhood brain tumors
#Text=Brain resting-state functional MRI connectivity: morphological foundation and plasticity
#Text=Abnormal regional homogeneity in Parkinson's disease: a resting state fMRI study
#Text=A human brain atlas derived via n-cut parcellation of resting-state and task-based fmri data
#Text=Higher dimensional meta-state analysis reveals reduced resting fmri connectivity dynamism in schizophrenia patients
#Text=The neural mechanisms underlying the acute effect of cigarette smoking on chronic smokers
#Text=An fmri study of nicotine-deprived smokers' reactivity to smoking cues during novel/exciting activity
#Text=Regional homogeneity approach to fmri data analysis
#Text=Severity of nicotine dependence modulates cue-induced brain activity in regions involved in motor preparation and imagery
#Text=Altered spontaneous activity of posterior cingulate cortex and superior temporal gyrus are associated with a smoking cessation treatment outcome using varenicline revealed by regional homogeneity
#Text=Individual differences in nicotine dependence, withdrawal symptoms, and sex predict transient fmri-bold responses to smoking cues
#Text=Regional homogeneity changes in heavy male smokers: a resting-state functional magnetic resonance imaging study
#Text=Frequency of cigarette smoking among psychiatric inpatients evaluated by the fagerstr?
115-1	15991-16001	References	_	
115-2	16002-16005	The	_	
115-3	16006-16012	Health	_	
115-4	16013-16025	Consequences	_	
115-5	16026-16028	of	_	
115-6	16029-16036	Smoking	_	
115-7	16036-16037	:	_	
115-8	16038-16039	A	_	
115-9	16040-16046	Report	_	
115-10	16047-16049	of	_	
115-11	16050-16053	the	_	
115-12	16054-16061	Surgeon	_	
115-13	16062-16069	General	_	
115-14	16070-16077	elegans	_	
115-15	16078-16081	and	_	
115-16	16082-16089	mutants	_	
115-17	16090-16094	with	_	
115-18	16095-16102	chronic	_	
115-19	16103-16111	nicotine	_	
115-20	16112-16120	exposure	_	
115-21	16121-16123	as	_	
115-22	16124-16125	a	_	
115-23	16126-16131	novel	_	
115-24	16132-16137	model	_	
115-25	16138-16140	of	_	
115-26	16141-16147	cancer	_	
115-27	16148-16157	phenotype	_	
115-28	16158-16167	Cigarette	_	
115-29	16168-16175	smoking	_	
115-30	16176-16181	leads	_	
115-31	16182-16184	to	_	
115-32	16185-16195	persistent	_	
115-33	16196-16199	and	_	
115-34	16200-16214	dose-dependent	_	
115-35	16215-16226	alterations	_	
115-36	16227-16229	of	_	
115-37	16230-16235	brain	_	
115-38	16236-16244	activity	_	
115-39	16245-16248	and	_	
115-40	16249-16261	connectivity	_	
115-41	16262-16264	in	_	
115-42	16265-16273	anterior	_	
115-43	16274-16280	insula	_	
115-44	16281-16284	and	_	
115-45	16285-16293	anterior	_	
115-46	16294-16303	cingulate	_	
115-47	16304-16310	Neural	_	
115-48	16311-16322	sensitivity	_	
115-49	16323-16325	to	_	
115-50	16326-16333	smoking	_	
115-51	16334-16341	stimuli	_	
115-52	16342-16344	is	_	
115-53	16345-16355	associated	_	
115-54	16356-16360	with	_	
115-55	16361-16370	cigarette	_	
115-56	16371-16378	craving	_	
115-57	16379-16381	in	_	
115-58	16382-16392	adolescent	_	
115-59	16393-16400	smokers	_	
115-60	16401-16408	Chronic	_	
115-61	16409-16418	cigarette	_	
115-62	16419-16426	smoking	_	
115-63	16427-16429	is	_	
115-64	16430-16436	linked	_	
115-65	16437-16441	with	_	
115-66	16442-16452	structural	_	
115-67	16453-16464	alterations	_	
115-68	16465-16467	in	_	
115-69	16468-16473	brain	_	
115-70	16474-16481	regions	_	
115-71	16482-16489	showing	_	
115-72	16490-16495	acute	_	
115-73	16496-16505	nicotinic	_	
115-74	16506-16518	drug-induced	_	
115-75	16519-16529	functional	_	
115-76	16530-16541	modulations	_	
115-77	16542-16545	The	_	
115-78	16546-16553	effects	_	
115-79	16554-16556	of	_	
115-80	16557-16565	nicotine	_	
115-81	16566-16569	and	_	
115-82	16570-16582	non-nicotine	_	
115-83	16583-16590	smoking	_	
115-84	16591-16598	factors	_	
115-85	16599-16601	on	_	
115-86	16602-16609	working	_	
115-87	16610-16616	memory	_	
115-88	16617-16620	and	_	
115-89	16621-16631	associated	_	
115-90	16632-16637	brain	_	
115-91	16638-16646	function	_	
115-92	16647-16658	Spontaneous	_	
115-93	16659-16671	fluctuations	_	
115-94	16672-16674	in	_	
115-95	16675-16680	brain	_	
115-96	16681-16689	activity	_	
115-97	16690-16698	observed	_	
115-98	16699-16703	with	_	
115-99	16704-16714	functional	_	
115-100	16715-16723	magnetic	_	
115-101	16724-16733	resonance	_	
115-102	16734-16741	imaging	_	
115-103	16742-16752	Functional	_	
115-104	16753-16756	and	_	
115-105	16757-16766	effective	_	
115-106	16767-16779	connectivity	_	
115-107	16779-16780	:	_	
115-108	16781-16782	a	_	
115-109	16783-16789	review	_	
115-110	16790-16799	Increased	_	
115-111	16800-16807	frontal	_	
115-112	16808-16818	functional	_	
115-113	16819-16827	networks	_	
115-114	16828-16830	in	_	
115-115	16831-16836	adult	_	
115-116	16837-16846	survivors	_	
115-117	16847-16849	of	_	
115-118	16850-16859	childhood	_	
115-119	16860-16865	brain	_	
115-120	16866-16872	tumors	_	
115-121	16873-16878	Brain	_	
115-122	16879-16892	resting-state	_	
115-123	16893-16903	functional	_	
115-124	16904-16907	MRI	_	
115-125	16908-16920	connectivity	_	
115-126	16920-16921	:	_	
115-127	16922-16935	morphological	_	
115-128	16936-16946	foundation	_	
115-129	16947-16950	and	_	
115-130	16951-16961	plasticity	_	
115-131	16962-16970	Abnormal	_	
115-132	16971-16979	regional	_	
115-133	16980-16991	homogeneity	_	
115-134	16992-16994	in	_	
115-135	16995-17006	Parkinson's	_	
115-136	17007-17014	disease	_	
115-137	17014-17015	:	_	
115-138	17016-17017	a	_	
115-139	17018-17025	resting	_	
115-140	17026-17031	state	_	
115-141	17032-17036	fMRI	_	
115-142	17037-17042	study	_	
115-143	17043-17044	A	_	
115-144	17045-17050	human	_	
115-145	17051-17056	brain	_	
115-146	17057-17062	atlas	_	
115-147	17063-17070	derived	_	
115-148	17071-17074	via	_	
115-149	17075-17080	n-cut	_	
115-150	17081-17093	parcellation	_	
115-151	17094-17096	of	_	
115-152	17097-17110	resting-state	_	
115-153	17111-17114	and	_	
115-154	17115-17125	task-based	_	
115-155	17126-17130	fmri	_	
115-156	17131-17135	data	_	
115-157	17136-17142	Higher	_	
115-158	17143-17154	dimensional	_	
115-159	17155-17165	meta-state	_	
115-160	17166-17174	analysis	_	
115-161	17175-17182	reveals	_	
115-162	17183-17190	reduced	_	
115-163	17191-17198	resting	_	
115-164	17199-17203	fmri	_	
115-165	17204-17216	connectivity	_	
115-166	17217-17225	dynamism	_	
115-167	17226-17228	in	_	
115-168	17229-17242	schizophrenia	_	
115-169	17243-17251	patients	_	
115-170	17252-17255	The	_	
115-171	17256-17262	neural	_	
115-172	17263-17273	mechanisms	_	
115-173	17274-17284	underlying	_	
115-174	17285-17288	the	_	
115-175	17289-17294	acute	_	
115-176	17295-17301	effect	_	
115-177	17302-17304	of	_	
115-178	17305-17314	cigarette	_	
115-179	17315-17322	smoking	_	
115-180	17323-17325	on	_	
115-181	17326-17333	chronic	_	
115-182	17334-17341	smokers	_	
115-183	17342-17344	An	_	
115-184	17345-17349	fmri	_	
115-185	17350-17355	study	_	
115-186	17356-17358	of	_	
115-187	17359-17376	nicotine-deprived	_	
115-188	17377-17384	smokers	_	
115-189	17384-17385	'	_	
115-190	17386-17396	reactivity	_	
115-191	17397-17399	to	_	
115-192	17400-17407	smoking	_	
115-193	17408-17412	cues	_	
115-194	17413-17419	during	_	
115-195	17420-17425	novel	_	
115-196	17425-17426	/	_	
115-197	17426-17434	exciting	_	
115-198	17435-17443	activity	_	
115-199	17444-17452	Regional	_	
115-200	17453-17464	homogeneity	_	
115-201	17465-17473	approach	_	
115-202	17474-17476	to	_	
115-203	17477-17481	fmri	_	
115-204	17482-17486	data	_	
115-205	17487-17495	analysis	_	
115-206	17496-17504	Severity	_	
115-207	17505-17507	of	_	
115-208	17508-17516	nicotine	_	
115-209	17517-17527	dependence	_	
115-210	17528-17537	modulates	_	
115-211	17538-17549	cue-induced	_	
115-212	17550-17555	brain	_	
115-213	17556-17564	activity	_	
115-214	17565-17567	in	_	
115-215	17568-17575	regions	_	
115-216	17576-17584	involved	_	
115-217	17585-17587	in	_	
115-218	17588-17593	motor	_	
115-219	17594-17605	preparation	_	
115-220	17606-17609	and	_	
115-221	17610-17617	imagery	_	
115-222	17618-17625	Altered	_	
115-223	17626-17637	spontaneous	_	
115-224	17638-17646	activity	_	
115-225	17647-17649	of	_	
115-226	17650-17659	posterior	_	
115-227	17660-17669	cingulate	_	
115-228	17670-17676	cortex	_	
115-229	17677-17680	and	_	
115-230	17681-17689	superior	_	
115-231	17690-17698	temporal	_	
115-232	17699-17704	gyrus	_	
115-233	17705-17708	are	_	
115-234	17709-17719	associated	_	
115-235	17720-17724	with	_	
115-236	17725-17726	a	_	
115-237	17727-17734	smoking	_	
115-238	17735-17744	cessation	_	
115-239	17745-17754	treatment	_	
115-240	17755-17762	outcome	_	
115-241	17763-17768	using	_	
115-242	17769-17780	varenicline	_	
115-243	17781-17789	revealed	_	
115-244	17790-17792	by	_	
115-245	17793-17801	regional	_	
115-246	17802-17813	homogeneity	_	
115-247	17814-17824	Individual	_	
115-248	17825-17836	differences	_	
115-249	17837-17839	in	_	
115-250	17840-17848	nicotine	_	
115-251	17849-17859	dependence	_	
115-252	17859-17860	,	_	
115-253	17861-17871	withdrawal	_	
115-254	17872-17880	symptoms	_	
115-255	17880-17881	,	_	
115-256	17882-17885	and	_	
115-257	17886-17889	sex	_	
115-258	17890-17897	predict	_	
115-259	17898-17907	transient	_	
115-260	17908-17917	fmri-bold	_	
115-261	17918-17927	responses	_	
115-262	17928-17930	to	_	
115-263	17931-17938	smoking	_	
115-264	17939-17943	cues	_	
115-265	17944-17952	Regional	_	
115-266	17953-17964	homogeneity	_	
115-267	17965-17972	changes	_	
115-268	17973-17975	in	_	
115-269	17976-17981	heavy	_	
115-270	17982-17986	male	_	
115-271	17987-17994	smokers	_	
115-272	17994-17995	:	_	
115-273	17996-17997	a	_	
115-274	17998-18011	resting-state	_	
115-275	18012-18022	functional	_	
115-276	18023-18031	magnetic	_	
115-277	18032-18041	resonance	_	
115-278	18042-18049	imaging	_	
115-279	18050-18055	study	_	
115-280	18056-18065	Frequency	_	
115-281	18066-18068	of	_	
115-282	18069-18078	cigarette	_	
115-283	18079-18086	smoking	_	
115-284	18087-18092	among	_	
115-285	18093-18104	psychiatric	_	
115-286	18105-18115	inpatients	_	
115-287	18116-18125	evaluated	_	
115-288	18126-18128	by	_	
115-289	18129-18132	the	_	
115-290	18133-18141	fagerstr	_	
115-291	18141-18142	?	_	

#Text=m test for nicotine dependence
#Text=The fagerstrom test for nicotine dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data
#Text=DPARSF: A MATLAB Toolbox for "Pipeline" Data Analysis of Resting-State fMRI
#Text=REST: a toolkit for resting-state functional magnetic resonance imaging data processing
#Text=Potential biomarkers of schizophrenia from meg resting-state functional connectivity networks: preliminary data
#Text=Altered cerebellar-amygdala connectivity in violent offenders: a resting-state fmri study
#Text=Regional homogeneity of resting-state brain abnormalities in violent juvenile offenders: a biomarker of brain immaturity?
116-1	18142-18143	m	_	
116-2	18144-18148	test	_	
116-3	18149-18152	for	_	
116-4	18153-18161	nicotine	_	
116-5	18162-18172	dependence	_	
116-6	18173-18176	The	_	
116-7	18177-18187	fagerstrom	_	
116-8	18188-18192	test	_	
116-9	18193-18196	for	_	
116-10	18197-18205	nicotine	_	
116-11	18206-18216	dependence	_	
116-12	18217-18219	as	_	
116-13	18220-18221	a	_	
116-14	18222-18231	predictor	_	
116-15	18232-18234	of	_	
116-16	18235-18242	smoking	_	
116-17	18243-18253	abstinence	_	
116-18	18253-18254	:	_	
116-19	18255-18256	a	_	
116-20	18257-18263	pooled	_	
116-21	18264-18272	analysis	_	
116-22	18273-18275	of	_	
116-23	18276-18287	varenicline	_	
116-24	18288-18296	clinical	_	
116-25	18297-18302	trial	_	
116-26	18303-18307	data	_	
116-27	18308-18314	DPARSF	_	
116-28	18314-18315	:	_	
116-29	18316-18317	A	_	
116-30	18318-18324	MATLAB	_	
116-31	18325-18332	Toolbox	_	
116-32	18333-18336	for	_	
116-33	18337-18338	"	_	
116-34	18338-18346	Pipeline	_	
116-35	18346-18347	"	_	
116-36	18348-18352	Data	_	
116-37	18353-18361	Analysis	_	
116-38	18362-18364	of	_	
116-39	18365-18378	Resting-State	_	
116-40	18379-18383	fMRI	_	
116-41	18384-18388	REST	_	
116-42	18388-18389	:	_	
116-43	18390-18391	a	_	
116-44	18392-18399	toolkit	_	
116-45	18400-18403	for	_	
116-46	18404-18417	resting-state	_	
116-47	18418-18428	functional	_	
116-48	18429-18437	magnetic	_	
116-49	18438-18447	resonance	_	
116-50	18448-18455	imaging	_	
116-51	18456-18460	data	_	
116-52	18461-18471	processing	_	
116-53	18472-18481	Potential	_	
116-54	18482-18492	biomarkers	_	
116-55	18493-18495	of	_	
116-56	18496-18509	schizophrenia	_	
116-57	18510-18514	from	_	
116-58	18515-18518	meg	_	
116-59	18519-18532	resting-state	_	
116-60	18533-18543	functional	_	
116-61	18544-18556	connectivity	_	
116-62	18557-18565	networks	_	
116-63	18565-18566	:	_	
116-64	18567-18578	preliminary	_	
116-65	18579-18583	data	_	
116-66	18584-18591	Altered	_	
116-67	18592-18611	cerebellar-amygdala	_	
116-68	18612-18624	connectivity	_	
116-69	18625-18627	in	_	
116-70	18628-18635	violent	_	
116-71	18636-18645	offenders	_	
116-72	18645-18646	:	_	
116-73	18647-18648	a	_	
116-74	18649-18662	resting-state	_	
116-75	18663-18667	fmri	_	
116-76	18668-18673	study	_	
116-77	18674-18682	Regional	_	
116-78	18683-18694	homogeneity	_	
116-79	18695-18697	of	_	
116-80	18698-18711	resting-state	_	
116-81	18712-18717	brain	_	
116-82	18718-18731	abnormalities	_	
116-83	18732-18734	in	_	
116-84	18735-18742	violent	_	
116-85	18743-18751	juvenile	_	
116-86	18752-18761	offenders	_	
116-87	18761-18762	:	_	
116-88	18763-18764	a	_	
116-89	18765-18774	biomarker	_	
116-90	18775-18777	of	_	
116-91	18778-18783	brain	_	
116-92	18784-18794	immaturity	_	
116-93	18794-18795	?	_	

#Text=Abnormal regional homogeneity in parkinson's disease: a resting state fmri study
#Text=Decreased regional homogeneity in patients with acute mild traumatic brain injury: a resting-state fmri study
#Text=Regional homogeneity of resting-state brain abnormalities in bipolar and unipolar depression
#Text=Regional homogeneity changes in amnestic mild cognitive impairment patients
#Text=Machine learning classification of cirrhotic patients with and without minimal hepatic encephalopathy based on regional homogeneity of intrinsic brain activity
#Text=Structural efficiency within a parieto-frontal network and cognitive differences
#Text=Tms over the right precuneus reduces the bilateral field advantage in visual short term memory capacity
#Text=Facilitation of performance in a working memory task with rtms stimulation of the precuneus: frequency- and time-dependent effects
#Text=Precuneus hypoperfusion plays an important role in memory impairment of patients with systemic lupus erythematosus
117-1	18796-18804	Abnormal	_	
117-2	18805-18813	regional	_	
117-3	18814-18825	homogeneity	_	
117-4	18826-18828	in	_	
117-5	18829-18840	parkinson's	_	
117-6	18841-18848	disease	_	
117-7	18848-18849	:	_	
117-8	18850-18851	a	_	
117-9	18852-18859	resting	_	
117-10	18860-18865	state	_	
117-11	18866-18870	fmri	_	
117-12	18871-18876	study	_	
117-13	18877-18886	Decreased	_	
117-14	18887-18895	regional	_	
117-15	18896-18907	homogeneity	_	
117-16	18908-18910	in	_	
117-17	18911-18919	patients	_	
117-18	18920-18924	with	_	
117-19	18925-18930	acute	_	
117-20	18931-18935	mild	_	
117-21	18936-18945	traumatic	_	
117-22	18946-18951	brain	_	
117-23	18952-18958	injury	_	
117-24	18958-18959	:	_	
117-25	18960-18961	a	_	
117-26	18962-18975	resting-state	_	
117-27	18976-18980	fmri	_	
117-28	18981-18986	study	_	
117-29	18987-18995	Regional	_	
117-30	18996-19007	homogeneity	_	
117-31	19008-19010	of	_	
117-32	19011-19024	resting-state	_	
117-33	19025-19030	brain	_	
117-34	19031-19044	abnormalities	_	
117-35	19045-19047	in	_	
117-36	19048-19055	bipolar	_	
117-37	19056-19059	and	_	
117-38	19060-19068	unipolar	_	
117-39	19069-19079	depression	_	
117-40	19080-19088	Regional	_	
117-41	19089-19100	homogeneity	_	
117-42	19101-19108	changes	_	
117-43	19109-19111	in	_	
117-44	19112-19120	amnestic	_	
117-45	19121-19125	mild	_	
117-46	19126-19135	cognitive	_	
117-47	19136-19146	impairment	_	
117-48	19147-19155	patients	_	
117-49	19156-19163	Machine	_	
117-50	19164-19172	learning	_	
117-51	19173-19187	classification	_	
117-52	19188-19190	of	_	
117-53	19191-19200	cirrhotic	_	
117-54	19201-19209	patients	_	
117-55	19210-19214	with	_	
117-56	19215-19218	and	_	
117-57	19219-19226	without	_	
117-58	19227-19234	minimal	_	
117-59	19235-19242	hepatic	_	
117-60	19243-19257	encephalopathy	_	
117-61	19258-19263	based	_	
117-62	19264-19266	on	_	
117-63	19267-19275	regional	_	
117-64	19276-19287	homogeneity	_	
117-65	19288-19290	of	_	
117-66	19291-19300	intrinsic	_	
117-67	19301-19306	brain	_	
117-68	19307-19315	activity	_	
117-69	19316-19326	Structural	_	
117-70	19327-19337	efficiency	_	
117-71	19338-19344	within	_	
117-72	19345-19346	a	_	
117-73	19347-19362	parieto-frontal	_	
117-74	19363-19370	network	_	
117-75	19371-19374	and	_	
117-76	19375-19384	cognitive	_	
117-77	19385-19396	differences	_	
117-78	19397-19400	Tms	_	
117-79	19401-19405	over	_	
117-80	19406-19409	the	_	
117-81	19410-19415	right	_	
117-82	19416-19425	precuneus	_	
117-83	19426-19433	reduces	_	
117-84	19434-19437	the	_	
117-85	19438-19447	bilateral	_	
117-86	19448-19453	field	_	
117-87	19454-19463	advantage	_	
117-88	19464-19466	in	_	
117-89	19467-19473	visual	_	
117-90	19474-19479	short	_	
117-91	19480-19484	term	_	
117-92	19485-19491	memory	_	
117-93	19492-19500	capacity	_	
117-94	19501-19513	Facilitation	_	
117-95	19514-19516	of	_	
117-96	19517-19528	performance	_	
117-97	19529-19531	in	_	
117-98	19532-19533	a	_	
117-99	19534-19541	working	_	
117-100	19542-19548	memory	_	
117-101	19549-19553	task	_	
117-102	19554-19558	with	_	
117-103	19559-19563	rtms	_	
117-104	19564-19575	stimulation	_	
117-105	19576-19578	of	_	
117-106	19579-19582	the	_	
117-107	19583-19592	precuneus	_	
117-108	19592-19593	:	_	
117-109	19594-19603	frequency	_	
117-110	19603-19604	-	_	
117-111	19605-19608	and	_	
117-112	19609-19623	time-dependent	_	
117-113	19624-19631	effects	_	
117-114	19632-19641	Precuneus	_	
117-115	19642-19655	hypoperfusion	_	
117-116	19656-19661	plays	_	
117-117	19662-19664	an	_	
117-118	19665-19674	important	_	
117-119	19675-19679	role	_	
117-120	19680-19682	in	_	
117-121	19683-19689	memory	_	
117-122	19690-19700	impairment	_	
117-123	19701-19703	of	_	
117-124	19704-19712	patients	_	
117-125	19713-19717	with	_	
117-126	19718-19726	systemic	_	
117-127	19727-19732	lupus	_	
117-128	19733-19746	erythematosus	_	
